<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        10-355-01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        METHOTREXATE "EBEWE" 100MG-ML VIAL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        METHOTREXATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1304.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value=" Fareva Unterach GmbH " />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                             Fareva Unterach GmbH 
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            EBEWE PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Methotrexat Ebewe 100&nbsp;mg/ml is a medicine with the following properties:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it inhibits the growth of certain cells in the body that rapidly multiply (anti-cancer active substance)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it reduces the adverse reactions of the body&rsquo;s own defence system (immunosuppressant) and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it has an anti-inflammatory effect</p><p>&nbsp;</p><p>Methotrexat Ebewe 100&nbsp;mg/ml is used in adults, adolescents and children from 3 months (solely intrathecal administration, see Section 3) alone or in combination with other medicines to treat certain types of cancer, such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gynaecological cancers</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast cancer</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; head and neck tumours</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer in the lymphatic system (non-Hodgkin&rsquo;s lymphoma, primary central nervous system lymphoma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leukaemia (acute lymphatic leukaemia [ALL], meningeal leukaemia)</p><p>&nbsp;</p><p>Methotrexat Ebewe tablets, Methotrexat Ebewe 20&nbsp;mg/ml solution for injection in a pre-filled syringe, Methotrexat Ebewe 10&nbsp;mg/ml parenteral solution or Methotrexat Ebewe 10&nbsp;mg/ml solution for injection in a pre-filled syringe are suitable for use in severe generalised refractory psoriasis, psoriatic arthritis and rheumatoid arthritis.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Methotrexat &ldquo;Ebewe&rdquo; </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to methotrexate or any of the other ingredients of this medicine listed in Section 6</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from a severe, acute or chronic infection, such as tuberculosis or HIV</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have an inflammation of the oral mucosa or you have ulcers in your oral cavity</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ulcers in the stomach/intestinal area</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe kidney disease (or your doctor has classified the disease as serious)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a severe liver disease (or your doctor has classified the disease as serious)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diseases of the haemopoietic system (e.g., after prior radiotherapy or chemotherapy)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a blood disorder</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the case of excessive alcohol consumption, alcohol-induced liver disease, or other chronic liver diseases</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from immune deficiency diseases (impaired functioning of the body&rsquo;s defence system)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are breastfeeding (see Section &ldquo;Pregnancy, breastfeeding and fertility&rdquo;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are pregnant (unless your doctor determines a life-threatening illness, see also Section &quot;Pregnancy, breastfeeding and fertility&quot;)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are being given a live vaccine at the same time</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Methotrexat Ebewe 100&nbsp;mg/ml should only be prescribed by doctors who have sufficient experience in treating the disease in question with methotrexate.</p><p>&nbsp;</p><p><u>Before treatment</u></p><p>Before starting treatment, your doctor will perform blood tests and check how well your kidneys and your liver work. You may also undergo an X-ray examination of the chest. During and after treatment, additional tests may be performed. In addition to the above examinations, examinations of the mouth and throat may also be added at this point. More frequent examination appointments may be necessary if your dose is increased. Do not miss your appointments for blood tests and other tests.</p><p>If the results of any of the tests are abnormal, the treatment is only resumed once all the values are normal again.</p><p>&nbsp;</p><p>Due to the possibility of serious toxic reactions (which can be fatal) in the treatment of patients with tumour diseases, Methotrexat Ebewe 100&nbsp;mg/ml should only be used in moderate and high dosages in patients with life-threatening tumour diseases. Deaths were reported during treatment with methotrexate in the treatment of tumour diseases.</p><p>&nbsp;</p><p>During treatment with Methotrexat Ebewe 100&nbsp;mg/ml, you must be closely observed so that any symptoms of intoxication can be detected quickly. In the event of symptoms of poisoning, a doctor must be consulted immediately, who decides on the monitoring and treatment of symptoms of poisoning, including regular laboratory tests, and informs you of further measures.</p><p>&nbsp;</p><p>The discontinuation of Methotrexat Ebewe 100&nbsp;mg/ml does not always lead to the full regression of the side effects.</p><p>&nbsp;</p><p><u>Recommended follow-up examinations and precautionary measures</u></p><p>Severe side effects may occur even if Methotrexat Ebewe 100&nbsp;mg/ml is administered in low doses. Your doctor must perform examinations and laboratory tests to detect these in time.</p><p>&nbsp;</p><p><u>Special precautions for treatment with Methotrexat Ebewe 100&nbsp;mg/ml</u></p><p>Methotrexate can have mutagenic effects. Methotrexate temporarily impairs the production of sperm and egg cells, which is reversible in most cases. Methotrexate can cause miscarriages and severe birth defects. You and your partner must avoid pregnancy or the conception of children during treatment with methotrexate and for at least 6 months after the end of treatment. See also Section &ldquo;Pregnancy, breastfeeding and fertility&rdquo;.</p><p>&nbsp;</p><p>Talk to your doctor before using Methotrexat Ebewe 100&nbsp;mg/ml</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes mellitus that is treated with insulin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from inactive, chronic infections (e.g., tuberculosis, hepatitis B or C, shingles [herpes zoster]) or chickenpox</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are exposed to pathogens of chickenpox or shingles</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from an active infection or skin disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have had a liver or kidney disease</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your lung function, develop cough or shortness of breath</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are particularly overweight</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have abnormal accumulation of fluid in the abdomen or in the cavity between the lungs and the chest wall (ascites, pleural effusions)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are dehydrated or suffer from circumstances that cause dehydration (vomiting, diarrhoea, inflammation of the oral mucosa)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you notice unusual bleeding or bruising, blood in the urine or red spots on the skin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you suffer from stomach ulcers, diarrhoea or vomiting of blood, your stool is black or contains blood</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are receiving/have received radiotherapy or are taking/have taken medicines that could damage bone marrow</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are receiving a vaccination. Live vaccines (e.g., measles, mumps, rubella) must not be administered during treatment with methotrexate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have problems with your immune system or do not feel well</p><p>&nbsp;</p><p><u>Skin diseases</u></p><p>If you had skin problems after radiotherapy (skin inflammation caused by radiation [dermatitis]) or after sunburn, these symptoms can occur again with a methotrexate therapy (&ldquo;recall&rdquo; reaction).</p><p>Changes in the skin caused by psoriasis may worsen during treatment with Methotrexat Ebewe if you are exposed to UV radiation at the same time.</p><p>Methotrexate can cause severe, occasionally fatal skin reactions that may occur even after a single administration.</p><p>&nbsp;</p><p><u>Liver function</u></p><p>Methotrexate can cause liver inflammation and chronic, potentially fatal liver diseases, generally only after prolonged use.</p><p>Since methotrexate can cause liver damage, the intake/use of medicines that attack the liver must be avoided during treatment. During the treatment with methotrexate, alcohol must be completely avoided.</p><p>If one of the following symptoms occurs, a doctor must be consulted immediately: inflammation of the oral mucosa, diarrhoea, blood in the stool, black staining of the stool, bloody sputum or coughing or vomiting of blood.</p><p>&nbsp;</p><p><u>Lung function</u></p><p>Treatment should be discontinued immediately if you suffer from a cough, fever, shortness of breath or chest pain or develop lung inflammation. Lung diseases triggered by methotrexate can occur at any time during therapy and cannot be always eliminated.</p><p>Acute lung bleeding was reported in patients with underlying rheumatological diseases in the use of methotrexate. Contact a doctor immediately if you observe signs of bloody sputum or coughing.</p><p>&nbsp;</p><p><u>Nervous system</u></p><p>Serious side effects that affect the brain or nervous system, such as headache, coma, paralysis symptoms and stroke, were observed during treatment with methotrexate. These side effects usually occurred in children and adolescents who received methotrexate in combination with a tumour medication (cytarabine).</p><p>If methotrexate is injected directly into the subarachnoid space (cavity system in the central nervous system, intrathecal), you will be monitored for signs of neurotoxicity (damage to the nervous system, such as meningeal irritation, temporary or persistent paralysis, brain diseases).</p><p>Temporary, acute neurological syndromes with symptoms such as abnormal behaviour, abnormal reflexes or focal sensory motor symptoms (including temporary blindness) were observed with high-dose methotrexate therapies.</p><p>In paediatric patients with acute lymphatic leukaemia, severe damage to the nervous system (neurotoxicity) may occur after with intravenous methotrexate treatment at moderately high doses, which is commonly reported as an epileptic seizure.</p><p>&nbsp;</p><p><u>Neoplasms</u></p><p>Pathological changes in the white brain matter were reported by patients and other diseases of the brain cannot be excluded.</p><p>Occasionally, the occurrence of malignant lymphoma was reported with the use of low-dosage methotrexate, which receded in some cases after the discontinuation of therapy with methotrexate.</p><p>In patients with rapidly growing tumours, methotrexate can cause metabolic disorders.</p><p>In the case of acute lymphatic leukaemia, methotrexate may induce pain in the left epigastric region (via inflammation of the splenic capsule).</p><p>&nbsp;</p><p><strong>Other medicines and Methotrexat Ebewe 100&nbsp;mg/ml</strong></p><p>Tell your doctor or pharmacist if you are taking/using, have recently taken/used or intend to take/use any other medicines.</p><p>&nbsp;</p><p>The simultaneous use of methotrexate with other medicines can lead to a mutual exacerbation or weakening of the effect, or possibly more intense side effects, and may cause serious physical damage under certain circumstances.</p><p>&nbsp;</p><p>Remember to tell your doctor about treatment with Methotrexat Ebewe 100&nbsp;mg/ml if you are prescribed another medicine during treatment. If medicines are prescribed by other physicians for the treatment of other diseases, this must always be reported to the doctor who is monitoring the methotrexate treatment.</p><p>&nbsp;</p><p>It is especially important to tell your doctor if you are taking/using the following medicines:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other drugs for rheumatoid arthritis or psoriasis, such as leflunomide, sulfasalazine (also administered for ulcerative colitis), aspirin (acetylsalicylic acid), phenylbutazone or amidopyrine (derivatives), gold compounds, penicillamine, hydroxychloroquine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal antiphlogistics (certain pain and anti-inflammatory medicines). Special caution is required, as there are reports of serious adverse events, including deaths, in connection with these</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Salicylates (analgesics with pain-relieving, antipyretic and anti-inflammatory effects)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Alcohol (should be avoided)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Live) vaccines</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Azathioprine (for the prevention of a rejection after an organ transplantation)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Retinoids (for the treatment of psoriasis and other skin diseases), such as etretinate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticonvulsants (such as phenytoin, levetiracetam; medicines used to treat seizures)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines for cancer (cytostatics such as cisplatin, procarbazine, L-asparaginase, 5‑fluorouracil, doxorubicin, vincristine, 6-mercaptopurine, bleomycin or cytarabine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Triamterene (diuretic medication)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Barbiturates (medicines for epilepsy and anaesthetics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nitrogen oxide-based anaesthetics (nitrous oxide; please talk to your doctor if you have an operation pending)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sedatives (tranquilisers)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The contraceptive pill</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid (for gout)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antibiotics such as: penicillin, sulphonamides, ciprofloxacin, pristinamycin, tetracyclines, chloramphenicol, cotrimoxazole</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyrimethamine (for the prevention and treatment of malaria)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vitamin products containing folic acid (derivatives) or folinic acid</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that can cause folic acid deficiency</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Proton pump inhibitors (including for the treatment of severe heartburn or severe ulcers), such as lansoprazole, omeprazole, or pantoprazole</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Theophylline (including for the treatment of asthma)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amiodarone (to treat arrhythmias)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coumarin-like blood clotting inhibitors (acenocoumarol, phenprocoumon)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metamizole (for the treatment of severe pain and fever)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Para-aminobenzoic acid (e.g., as a component of local anaesthetics)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P-aminohippuric acid (used in the examination of renal function)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Corticosteroids (&ldquo;cortisone&rdquo;) (for inflammatory and allergic diseases)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cholestyramine (for the treatment of increased cholesterol values)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erythrocyte concentrates (for blood transfusions)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Weak organic acids</p><p>&nbsp;</p><p>The risk of the occurrence of soft tissue necrosis, or osteonecrosis (death of soft or bony tissue), can be increased with radiotherapy during the use of methotrexate.</p><p>Patients who subsequently receive blood transfusions after methotrexate infusions over 24&nbsp;hours may experience increased toxicity due to prolonged serum methotrexate concentrations that are persistently high.</p><p>&nbsp;</p><p>Use of Methotrexat Ebewe 100&nbsp;mg/ml with food, drink and alcohol</p><p>No alcohol should be consumed during treatment with Methotrexat Ebewe 100&nbsp;mg/ml and excessive consumption of coffee, caffeine-containing soft drinks and black tea must be avoided.</p><p>Ensure that you drink plenty of fluid during treatment with Methotrexat Ebewe 100&nbsp;mg/ml because dehydration (reduced body water) can increase the toxicity of Methotrexat Ebewe 100&nbsp;mg/ml.</p><p>&nbsp;</p><p><strong>Pregnancy, breastfeeding and fertility</strong></p><p><u>Pregnancy</u></p><p>Do not use Methotrexat Ebewe during pregnancy unless your doctor has prescribed it for oncological treatment. Methotrexate can cause birth defects, harm the unborn child or trigger miscarriages. It is associated with malformations of the skull, face, heart and blood vessels, brain and limbs. Therefore, it is very important that methotrexate is not administered to pregnant women and patients who intend to become pregnant unless it is for oncological treatment.</p><p>For non-oncological indications, pregnancy must therefore be ruled out in women of childbearing age before the start of treatment with suitable methods, e.g., a pregnancy test.</p><p>Do not use Methotrexat Ebewe if you are trying to become pregnant. You must avoid becoming pregnant while using methotrexate and for at least 6 months after the end of treatment. Therefore, you must ensure that you use a reliable method of birth control (such as oral contraceptives like the &ldquo;pill&rdquo;) during this entire period (see also Section &ldquo;Warnings and precautions&rdquo;).</p><p>If you become pregnant during treatment or suspect that you could be pregnant, contact your doctor as quickly as possible. If you do become pregnant during treatment, you should be informed about the risk of harmful effects on the child during treatment.</p><p>If you wish to get pregnant, consult your doctor, who can transfer you to a specialist before the planned start of treatment.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Do not breastfeed during treatment because methotrexate passes into breast milk. If your treating physician considers treatment with methotrexate during breastfeeding to be unavoidable, you must stop breastfeeding.</p><p>&nbsp;</p><p><u>Male reproductive capacity</u></p><p>The available data does not indicate an increased risk of malformations or miscarriages if the father is treated weekly with less than 30&nbsp;mg methotrexate. However, a risk cannot be completely ruled out and there is no information in regard to methotrexate at higher doses. Methotrexate can have a genotoxic effect. This means that the medicine can cause genetic changes. Methotrexate can have a negative effect on sperm production with the possibility of causing birth defects. Therefore, you should avoid fathering a child or donating sperm during treatment with methotrexate and for at least 6 months after the end of treatment. Since usual methotrexate treatment for treating cancer diseases can lead to infertility and genetic mutations, it may be advisable for male patients being treated with doses that exceed 30&nbsp;mg/week to consider sperm preservation before starting treatment (see also Section &ldquo;Warnings and precautions&rdquo;).</p><p>&nbsp;</p><p><strong>Driving and operating machinery</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Title: Warndreick - Description: Symbol: Achtung" style='width:30.75pt;
 height:27pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF
90j8g+UtSpyyQAg16YLHEliUDxjsSWLhl2y3tH/PJE0kqEo33Vj2zNy5x2MvVztr2BZj0t7VfFFW
nKGTXmnX1fxj/VLcc5YyOAXGO6z5HhNfNddXy/U+YGKkdqnmfc7hQYgke7SQSh/QUab10UKmY+xE
APkFHYrbqroT0ruMLhd56MGb5RO2sDGZPe8ofCAJruPs8VA3WNVc20E/xMVJRUSTjiQQgtESMt1N
bJ064iomppKUY03qdUg3BP6Pw5D5y/TbYNK90TCjVsjeIeZXsEQupNHh00NUQkX4ptGmebMozzc9
Qe3bVktUXm4szbCcOs7Y5+0zvQ+Kcb3ceWwz+4rxPzQ/AAAA//8DAFBLAwQUAAYACAAAACEArTA/
8cEAAAAyAQAACwAAAF9yZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj
39ubi6AgeJtl2G9m6vYxjeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLB
BhaZ4ljBkFLYSMl6oAm58IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZ
TVuvrxO59CNCmoj3vCwjMfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAA
ACEAAMwf8CsCAACsBAAAHwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWykVF1r2zAU
fR/sPwi9J7YTt0lMnZIlaRl0W1g39qzIsi2qDyPJbkLZf9+VP9KQjQ26F3Olq3t07rnHurk9SIEa
ZizXKsXROMSIKaozrooUf/92N5pjZB1RGRFasRQfmcW3y/fvbkhSGFKVnCJAUDYhKS6dq5IgsLRk
ktixrpiCXK6NJA6WpggyQ54BWYpgEobXgSRc4eUr1IY4gmrD3wAlNH1i2ZqohliAFDQ53+k5Cvr/
yCRRzb2pHqud8czp52ZnEM9SDMopIkEiHPSJ/hgsg4uq4hXgkBvpz+s8R4cW5ei/LQY7OERhc7qI
ZosrjCikpnF0Pe3ztPzyhypabv9aB2S6SyE4I1Jx6nmoZsfpZW/R0BvkXG0Ygo2MWWpS/HiUey0S
tKKlq1WBkeNOgAo/iFGZYZw+nfRogQc1TrfsBa/uuBD+ch/3swLof/sJROOUbTStJVOuM5Vhgjhw
sy15ZTEyCZN7BvMxH7OoNRuo+mCdv87r29rtZTJfheFi8mG0vgrXozicbUerRTwbzcLtLA7jebSO
1j99dRQntWUPmhKxqfjg/Sj+ja3k1GirczemWgYd0cH/QDQKO/ejhoh+3jAOINSaZaAIW14Sz9U6
wxwtfZiDWl8ZdZ2Up0R/eNDSgkPR/vmTzmAapHa6bf7tdgP4obgy1t0zLZEPQFng0oKTBoTtWA1H
PF+lPaeebfvfAFbl7RZc/Kdt8/274h+D8/XyFwAAAP//AwBQSwMEFAAGAAgAAAAhAFNSiWHSAAAA
qwEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOskMFKBDEM
hu+C71Byt5nZg4hsZy8i7FXWBwhtplOcpqWt4r691b04sODFSyAJ+fLx7w+fcVUfXGpIYmDUAygW
m1wQb+D19Hz3AKo2EkdrEjZw5gqH6fZm/8IrtX5Ul5Cr6hSpBpbW8iNitQtHqjpllr6ZU4nUels8
ZrJv5Bl3w3CP5TcDpg1THZ2BcnQ7UKdz7p//Zqd5Dpafkn2PLO3KC2zdizuQiudmQOvL5FJH3V0B
r2uM/6kRYo9goxHZBcKf+aiz+G8N3EQ8fQEAAP//AwBQSwMEFAAGAAgAAAAhAJxOXiHiBgAAOhwA
ABoAAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbOxZT28bRRS/I/EdRntv4/+NozpV7NgNtGmj
2C3qcbwe704zu7OaGSf1DbVHJCREQRyoxI0DAiq1EpfyaQJFUKR+Bd7M7K534jVJ2wgqaA7x7tvf
vP/vzZvdy1fuRQwdEiEpjzte9WLFQyT2+YTGQce7NRpcWPeQVDieYMZj0vHmRHpXNt9/7zLe8BlN
xhyLySgkEUHAKJYbuOOFSiUba2vSBzKWF3lCYng25SLCCm5FsDYR+AgERGytVqm01iJMY28TOCrN
qM/gX6ykJvhMDDUbgmIcgfSb0yn1icFODqoaIeeyxwQ6xKzjAc8JPxqRe8pDDEsFDzpexfx5a5uX
1/BGuoipFWsL6wbmL12XLpgc1IxMEYxzodVBo31pO+dvAEwt4/r9fq9fzfkZAPZ9sNTqUuTZGKxX
uxnPAsheLvPuVZqVhosv8K8v6dzudrvNdqqLZWpA9rKxhF+vtBpbNQdvQBbfXMI3ulu9XsvBG5DF
t5bwg0vtVsPFG1DIaHywhNYBHQxS7jlkytlOKXwd4OuVFL5AQTbk2aVFTHmsVuVahO9yMQCABjKs
aIzUPCFT7ENO9nA0FhRrAXiD4MITS/LlEknLQtIXNFEd78MEx14B8vLZ9y+fPUHH958e3//p+MGD
4/s/WkbOqh0cB8VVL7797M9HH6M/nnzz4uEX5XhZxP/6wye//Px5ORDKZ2He8y8f//b08fOvPv39
u4cl8C2Bx0X4iEZEohvkCO3zCAwzXnE1J2PxaitGIabFFVtxIHGMtZQS/n0VOugbc8zS6Dh6dInr
wdsC2kcZ8OrsrqPwMBQzRUskXwsjB7jLOetyUeqFa1pWwc2jWRyUCxezIm4f48My2T0cO/HtzxLo
m1laOob3QuKoucdwrHBAYqKQfsYPCCmx7g6ljl93qS+45FOF7lDUxbTUJSM6drJpsWiHRhCXeZnN
EG/HN7u3UZezMqu3yaGLhKrArET5EWGOG6/imcJRGcsRjljR4dexCsuUHM6FX8T1pYJIB4Rx1J8Q
KcvW3BRgbyHo1zB0rNKw77J55CKFogdlPK9jzovIbX7QC3GUlGGHNA6L2A/kAaQoRntclcF3uVsh
+h7igOOV4b5NiRPu07vBLRo4Ki0SRD+ZiZJYXiXcyd/hnE0xMa0GmrrTqyMa/13jZhQ6t5Vwfo0b
WuXzrx+V6P22tuwt2L3KambnRKNehTvZnntcTOjb35238SzeI1AQy1vUu+b8rjl7//nmvKqez78l
L7owNGg9i9hB24zd0cqpe0oZG6o5I9elGbwl7D2TARD1OnO6JPkpLAnhUlcyCHBwgcBmDRJcfURV
OAxxAkN71dNMApmyDiRKuITDoiGX8tZ4GPyVPWo29SHEdg6J1S6fWHJdk7OzRs7GaBWYA20mqK4Z
nFVY/VLKFGx7HWFVrdSZpVWNaqYpOtJyk7WLzaEcXJ6bBsTcmzDUIBiFwMstON9r0XDYwYxMtN9t
jLKwmCicZ4hkiCckjZG2ezlGVROkLFeWDNF22GTQB8dTvFaQ1tZs30DaWYJUFNdYIS6L3ptEKcvg
RZSA28lyZHGxOFmMjjpeu1lresjHScebwjkZLqMEoi71HIlZAG+YfCVs2p9azKbKF9FsZ4a5RVCF
Vx/W70sGO30gEVJtYxna1DCP0hRgsZZk9a81wa3nZUBJNzqbFvV1SIZ/TQvwoxtaMp0SXxWDXaBo
39nbtJXymSJiGE6O0JjNxD6G8OtUBXsmVMLrDtMR9A28m9PeNo/c5pwWXfGNmMFZOmZJiNN2q0s0
q2QLNw0p18HcFdQD20p1N8a9uimm5M/JlGIa/89M0fsJvH2oT3QEfHjRKzDSldLxuFAhhy6UhNQf
CBgcTO+AbIH3u/AYkgreSptfQQ71r605y8OUNRwi1T4NkKCwH6lQELIHbclk3ynMquneZVmylJHJ
qIK6MrFqj8khYSPdA1t6b/dQCKluuknaBgzuZP6592kFjQM95BTrzelk+d5ra+CfnnxsMYNRbh82
A03m/1zFfDxY7Kp2vVme7b1FQ/SDxZjVyKoChBW2gnZa9q+pwitutbZjLVlca2bKQRSXLQZiPhAl
8A4J6X+w/1HhM/sFQ2+oI74PvRXBxwvNDNIGsvqCHTyQbpCWOIbByRJtMmlW1rXp6KS9lm3W5zzp
5nJPOFtrdpZ4v6Kz8+HMFefU4nk6O/Ww42tLW+lqiOzJEgXSNDvImMCUfcnaxQkaB9WOB1+TIND3
4Aq+R3lAq2laTdPgCj4ywbBkvwx1vPQio8BzS8kx9YxSzzCNjNLIKM2MAsNZ+g0mo7SgU+nPJvDZ
Tv94KPtCAhNc+kUla6rO577NvwAAAP//AwBQSwMECgAAAAAAAAAhAPAsTkHjAwAA4wMAABoAAABj
bGlwYm9hcmQvbWVkaWEvaW1hZ2UxLnBuZ4lQTkcNChoKAAAADUlIRFIAAAApAAAAJAgGAAAAFP4T
KAAAAAFzUkdCAkDAfcUAAAAJcEhZcwAADsQAAA7EAZUrDhsAAAAZdEVYdFNvZnR3YXJlAE1pY3Jv
c29mdCBPZmZpY2V/7TVxAAADY0lEQVRYw9WYP2gaURzHRRL/k6hkUAhEyaBLQBzERYgQiDhIwUB0
0C1Zgi4KGTKkmRQcAl0El1DpXMd0akan4uhW6eTS1qaUCs3w+r5H3vF8ufPuTKrXLzw479/73M/f
7/t7d5arqyuL2YfpAV8UslQqZaxW6wNGsVjMmQ7y/Pzca7fbJxaLhWDYbLaftVotZCrIeDzeQQQZ
JN3+s7u7+8E0kKenpzEaxR8MkA3swzFTQG5vb/dFQDa8Xu/nlUMeHx+/4qPodrtJKpUi6+vrLJrf
8/l8aWWQzWbT4fF4xjzg5eUlGY/HZGNjQ46m0+n8hnNXArm/v/+aRuwXg/H7/WQ6nRIIsIDG/rW1
tWkikXizdEhqOQH6V94zwM3NTdLr9QgTYAHNFdE9rlkqJOwFNsMgotGoBHd7e0va7ba03e12ic/n
k0FDodDHpUFSW0nyxo0oDgYDCYrmKHE4HCSXy0mg4XCYj+YE1y4FErbCJkYVHx4eSkBbW1tEBO/3
+7ChZ1uSoZMzmUwFLY9NiipGNYtRA9jd3Z20P51OE75d4h7/DBI2AjthE+Kvpf1ZLpZkMkl4+OFw
KO0fjUYz0VzEkhbuz7zlQEdHRzKIy+WSIwydnJzAilhff8C9XhyyWq1G+SiialEovOr1+kxL5KVg
SRMjqyRdJ8E+eADkn6hGoyFHC0UkqtVqyQZv1JIM92dWuaJubm6kPFV7CCVLwkL52ZBIcAr1Rcly
RKGaWYGgiJSEroSHNGpJcw8eHBzU+f7MW44oRJcBoIjUxFsS7o05FoYU+7NoOaIAj6rGuSgiNfEP
83jfsVZfVz2wt7f3ju/PouUo6THXyPX19dzzjFqSrlcCPHmn0yFaQjpQq5KKaJ4U1pxf571qKO6k
FjLUshwlRSIRsrOzo5q3i1rSkx1Y7mPZz/dhLBS0NJlMpFzMZrOKFiUKqRMIBGZe3GB3mpBif8ZA
NepRuVyWr1Eycz2WBLtT6uszP7DMx3Jfj+WIisVi8mRYU2oVGRMWzFqWJG+gl/KLWUxUqVSIXiEq
qFg8WKFQ0H2daEkoItGSVPszBl6ojIyLiwtydnZm+Dr2CqxmSfLHJj6Kqx7i148nrwRmGTTH385A
0uR9T/Ppt1kAwcIXkPzpLhgMfjILJHKSt6L/4kvvX9E1PiYojjxCAAAAAElFTkSuQmCCUEsBAi0A
FAAGAAgAAAAhADQS/3gUAQAAUAIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54
bWxQSwECLQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAABFAQAAX3JlbHMvLnJl
bHNQSwECLQAUAAYACAAAACEAAMwf8CsCAACsBAAAHwAAAAAAAAAAAAAAAAAvAgAAY2xpcGJvYXJk
L2RyYXdpbmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQBTUolh0gAAAKsBAAAqAAAAAAAA
AAAAAAAAAJcEAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHNQSwEC
LQAUAAYACAAAACEAnE5eIeIGAAA6HAAAGgAAAAAAAAAAAAAAAACxBQAAY2xpcGJvYXJkL3RoZW1l
L3RoZW1lMS54bWxQSwECLQAKAAAAAAAAACEA8CxOQeMDAADjAwAAGgAAAAAAAAAAAAAAAADLDAAA
Y2xpcGJvYXJkL21lZGlhL2ltYWdlMS5wbmdQSwUGAAAAAAYABgCvAQAA5hAAAAAA
">
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png"
  o:title="" cropright="-320f"/>
</v:shape><![endif]--><img width="41" height="36" alt="Title: Warndreick - Description: Symbol: Achtung" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.gif" />Caution: This medicine may impair the ability to react and the ability to drive.</p><p>&nbsp;</p><p>During treatment with Methotrexat Ebewe 100&nbsp;mg/ml, the central nervous system may suffer side effects such as fatigue or fits of dizziness. Therefore, the ability to drive and use machines may be affected in some cases. If you feel tired or dizzy, do not drive or use machines. This is especially true if you consume alcohol during treatment with Methotrexat Ebewe.</p><p>&nbsp;</p><p><strong>Methotrexat Ebewe 100&nbsp;mg/ml contains sodium</strong></p><p>This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, i.e., it is essentially &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Methotrexat Ebewe 100&nbsp;mg/ml should only be used by doctors who are familiar with the different properties of the medicine and their mode of action.</p><p>&nbsp;</p><p><u>Dose for oncological diseases</u></p><p>Your doctor will determine the dose required for you according to your disease and general condition, as well as the blood count. <strong>This dose must be complied with exactly.</strong></p><p>Incorrect use of Methotrexat Ebewe can lead to severe, even fatal, side effects.</p><p>&nbsp;</p><p><u>Method and duration of administration</u></p><p>For intramuscular, intravenous, intra-arterial, intrathecal or intraventricular use.</p><p>Methotrexat Ebewe 100&nbsp;mg/ml may be administered into a muscle (intramuscular), a vein (intravenous), an artery (intra-arterial), the spinal column (intrathecal) and the cerebral ventricle (intraventricular).</p><p>The duration of treatment is determined by the treating physician.</p><p><u>&nbsp;</u></p><p><u>Use in children, adolescents and the elderly </u></p><p>The dosage instructions are based on the patient&rsquo;s body weight. Use in children under 3 years of age (except intrathecal administration) is not recommended because there are insufficient data for this age group.</p><p>Children and older people (over 55 years of age) who are treated with Methotrexat Ebewe 100&nbsp;mg/ml should be particularly closely monitored in order to detect possible side effects as early as possible.</p><p>Due to the decreased liver and kidney function, as well as low folate reserves in older people, a relatively low dosage should be chosen for older patients.</p><p>&nbsp;</p><p><strong>If you receive more Methotrexat Ebewe 100&nbsp;mg/ml than you should</strong></p><p>If you suspect that too much Methotrexat Ebewe was administered 100&nbsp;mg/ml, inform a doctor immediately. The doctor will decide on any necessary treatment measures depending on the severity of the intoxication.</p><p>An overdose of methotrexate can lead to serious symptoms of poisoning. The symptoms of an overdose may include an increased tendency to bleed or bleeding, unusual weakness, soreness of the mouth, nausea, vomiting, black or bloody stools, coughing blood or vomiting blood with the appearance of coffee grounds and reduced urination. After an overdose in the vertebral canal, CNS symptoms generally occur associated with headache, nausea and vomiting, seizures or convulsions and acute impaired function of the brain (toxic encephalopathy). See also Section&nbsp;4 &ldquo;Possible adverse reactions&rdquo;. Calcium folinate is the antidote in the event of an overdose.</p><p>&nbsp;</p><p><u>Information for the doctor:</u> See the end of this leaflet for information on overdoses.</p><p>&nbsp;</p><p><strong>If you stop using Methotrexat Ebewe</strong></p><p>Treatment with Methotrexat Ebewe must not be interrupted or discontinued unless your doctor has decided to do so. If you suspect serious side effects, contact a doctor immediately for advice.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medication, contact your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Many of these side effects can be severe, or even cause (sudden) death.</p><p>Therefore, your doctor will perform examinations of the kidneys or liver to identify any blood changes (e.g., low white blood cells, low value of blood platelets, lymphomas).</p><p>&nbsp;</p><p><strong>Inform a doctor immediately</strong> if you experience the following complaints, since they indicate a serious, potentially life-threatening side effect and must be treated immediately. Your doctor may decide to reduce the methotrexate dose or to stop your treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wheezing, shortness of breath, swelling of the eyelids, face or lips as well as rash or itching (especially affecting the entire body), since these can be signs of a severe allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung complaints including pneumonia (symptoms include general feeling of illness, dry cough, shortness of breath, shortness of breath when resting, respiratory arrest, chest pain or fever)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bloody sputum or coughing (reported with the use of methotrexate due to an underlying rheumatological disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Symptoms such as fever, sore throat, mouth ulcers, general feeling of illness and severe exhaustion, nosebleeds, or small red spots on the skin may be signs that your bone marrow is not functioning properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious peeling or blistering of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unusual bleeding (including vomiting of blood) or bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe diarrhoea (especially within the first 24&ndash;48&nbsp;hours after administration of methotrexate), severe complications in the gastrointestinal tract (toxic megacolon)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Black or tar-like stools</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in urine or stool</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow discolouration of the skin (jaundice)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain or difficulties while urinating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thirst and/or frequent urination&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of consciousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Transient blindness, loss of vision, blurred or impaired vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting and loss of muscle function (e.g., inability to move), as this can be signs of meningitis (brain inflammation)</p><p>&nbsp;</p><p>The following are further side effects that can occur:</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorders in blood cell formation with a decrease in the number of white blood cells (leukocytopenia) and/or platelets (thrombocytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, abdominal pain, diarrhoea (mainly within the first 24&ndash;48 hours after administration of methotrexate), nausea, vomiting, inflammation and ulceration of the mucous membranes of the mouth and throat (mainly within the first 24&ndash;48 hours after administration of methotrexate)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal values in blood tests for liver function (increase in liver enzymes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduced filtration rate of the kidneys (can be determined with a test by a doctor and shows worsening of renal function)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exhaustion, malaise</p><p>&nbsp;</p><p><strong>Common</strong> (may affect up to 1 in 10 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shingles (herpes zoster)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in red blood cells (anaemia), damage to bone marrow, which can lead to a severe drop in white blood cells (agranulocytosis) or all blood cells (pancytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drowsiness, discomfort/tingling (paraesthesia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the conjunctiva (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lung complications due to pneumonia (pneumonia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash, reddening of the skin, itching, increased sensitivity of the skin in sunlight (photosensitivity), skin ulcers</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infections as a result of a weakened defence reaction which can be fatal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malignant tumours in the lymphatic tissue (malignant lymphomas), which regressed in some cases after discontinuation of therapy with methotrexate</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions through to allergic shock, increase in infections/inflammation due to the suppression of the body&rsquo;s own defence system (immunosuppression)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes mellitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unilateral paralysis (hemiparesis), confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood vessel inflammation (vasculitis), allergic blood vessel inflammation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Connective tissue transformation of the lung tissue (pulmonary fibrosis), fluid accumulation between the pulmonary membranes (pleural effusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ulcers and bleeding in the gastrointestinal tract, inflammation of the pancreas (pancreatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver damage (hepatotoxicity), fatty liver, formation of scar tissue in the liver (liver fibrosis), conversion of liver tissue with scarring and decrease in liver function (liver cirrhosis), decrease in serum albumin (protein in the blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe and life-threatening skin reactions (Stevens-Johnson syndrome, Lyell&rsquo;s syndrome, fever-like skin symptoms), weals on the skin (urticaria), increased pigmentation of the skin, painful skin lesions under the skin (nodulosis), painful skin lesions in psoriasis, wound healing disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, muscle pain, reduction in bone mass (osteoporosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Severe kidney diseases, renal failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation and ulcers in the bladder, bladder emptying disorders, reduced or lack of production of urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Foetal malformations</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation and ulcers in the vaginal area</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With the intramuscular use of methotrexate, local side effects (burning sensation) or damage (formation of sterile abscesses, destruction of fatty tissues) at the administration site may occur</p><p>&nbsp;</p><p><strong>Rare </strong>(may affect up to 1 in 1000 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood poisoning (sepsis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Development and maturation disorder of red blood cells with anaemia (megaloblastic anaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mood swings, transient cognitive disorders</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Paralysis, speech disorders, pathological changes in the white brain matter (leukoencephalopathy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vision disorders (partly severe), occlusion of veins on the retina (retinal vein thrombosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decreased blood pressure (hypotension), occlusion of vessels by blood clots in veins and arteries (thrombosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation in the throat area, respiratory arrest, pulmonary embolism</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the digestive tract, bloody stools, inflamed gums</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute inflammation of the liver (hepatitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acne, point-shaped or small-area skin bleeding, inflammation of the skin (erythema multiforme), red skin rash, increased pigmentation of the nails, detachment of the nails from the nail bed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bone fracture due to stress</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increase in urea, creatinine and uric acid in the blood, increase in nitrogen-containing metabolic products in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Miscarriage</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reduction in sperm count and disorders of the female cycle, which, however, recede after the end of treatment</p><p>&nbsp;</p><p><strong>Very rare </strong>(may affect up to 1 in 10,000 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver inflammation caused by herpes viruses (herpes simplex hepatitis), infections caused by fungi (histoplasmosis, cryptococcus), by bacteria (nocardiosis), by viruses (cytomegalovirus infections, including pneumonia), widespread herpes simplex</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (aplastic anaemia), increase in certain white blood cells (eosinophilia), reduction in certain white blood cells (neutropenia), swelling of lymph nodes, lymphoproliferative diseases (excessive growth of certain white blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lack of antibodies in the blood (hypogammaglobulinaemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness and pain in the extremities</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metallic taste in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the cerebral skin with the consequence of paralysis or vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling around the eye cavity, eye eyelid inflammation, tear flow, increased sensitivity to light of the eyes, temporary blindness, loss of vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pericarditis, obstruction of cardiac filling by effusion in the pericardium (pericardial tamponade), fluid accumulation between the pericardial membranes (pericardial effusion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic disease of the lung tissue, asthma-like reactions with cough, difficulty breathing, abnormal findings after test of respiratory function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Death of liver cells (acute liver necrosis), liver decay, liver failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deep infection of hair follicles (furunculosis), visible, permanent expansion of the capillaries (telangiectasia), inflammation of the nail bed and fold</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in urine, increased protein excretion with urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the glands of sweat glands</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Malformation of egg or sperm cells, infertility, cycle disorders, loss of sexual interest (loss of libido), impotence, vaginal discharge, breast enlargement in men (gynaecomastia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The administration of methotrexate under the skin is well tolerated locally. Only mild skin reactions that abate during treatment were observed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Feeling numbness or tingling/less feeling when touched than usual</p><p>&nbsp;</p><p><strong>Not known </strong>(frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pneumonia, recurrence of a hepatitis B infection, worsening of a hepatitis C infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the abdominal cavity, severe complications in the large intestine (toxic megacolon), intestinal perforation, inflammation of the tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to the nervous system (neurotoxicity), inflammation of one of the cerebral membranes (arachnoiditis), loss of sensitivity and mobility of the legs (paraplegia), rigidity of the entire body (stupor), disorder in the orderly sequence and the coordination of muscle movements (ataxia), dementia, increased pressure in the brain spinal fluid (cerebrospinal fluid)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest pain, oxygen deficiency in the tissues (hypoxia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary bleeding (reported with the use of methotrexate with an underlying rheumatological disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drug reaction with rash on the entire body and an increase in eosinophils (a certain type of white blood cells) in the blood (so-called DRESS syndrome), inflammation of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Death of bone tissue (osteonecrosis) e.g., of the jaw</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dysfunction of urinary and sexual organs (urogenital dysfunction)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tissue damage at injection site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness and scaly skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chills</p><p>&nbsp;</p><p>The <strong>intrathecal and intravenous use </strong>of methotrexate can also lead to acute inflammation of the brain and acute pathological brain changes with a fatal outcome.</p><p>&nbsp;</p><p>With intrathecal use, damage to the central nervous system can occur which can manifest differently:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the cranial arachnoid mater (arachnoiditis) (with symptoms such as headache, back pain, neck stiffness and fever)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the spinal cord (with symptoms such as incomplete paralysis of the limbs, paraplegia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic pathological changes in the white brain substance (leukoencephalopathy) (with symptoms such as confusion, irritability, sleepiness, ataxia, dementia, seizures and coma). This damage can progress and lead to death</p><p>&nbsp;</p><p>There is some evidence that the combined use of cranial irradiation and intrathecal methotrexate increases the incidence of leukoencephalopathy (pathological changes of the white brain matter). After intrathecal administration, you must be monitored for possible signs of nerve damage (meningeal irritation, temporary or permanent paralysis, pathological brain changes).</p><p>&nbsp;</p><p>There are reports of patients with lymphomas in the central nervous system, in whom there were shifts of parts of the brain with intrathecal use of methotrexate.</p><p>&nbsp;</p><p>Inflammation of the skin caused by radiation and sunburn can recur with the use of methotrexate (so-called &ldquo;recall&rdquo; reactions).</p><p>&nbsp;</p><p>Methotrexate can reduce the number of white blood cells and therefore weaken immune defence. If you experience symptoms of an infection, such as fever or a severe worsening of your general condition or fever with local signs of an infection such as throat pain/inflammation in the throat or mouth or problems urinating, consult your doctor immediately.</p><p>A blood test will be performed to determine a possible reduction in white blood cells. It is important to inform your doctor about your medicines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store below 25&deg;C.</p><p>Store in the original packaging in order to protect from light.</p><p>Keep this medication out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is listed on the carton or label after &ldquo;EXP&rdquo;. The expiry date refers to the last day of the month specified.</p><p>&nbsp;</p><p>The medicinal product must be used immediately after opening.</p><p>Do not use Methotrexat Ebewe 100&nbsp;mg/ml if the solution is not clear and contains particles. For single use only. Dispose of any unused product.</p><p>Unused medicines or waste materials should be disposed of according to national regulations for cytotoxic substances.</p><p>The solution must not come into contact with the skin or mucous membranes.</p><p>Pregnant healthcare professionals must neither handle methotrexate nor administer it.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is methotrexate. 1&nbsp;ml contains 100&nbsp;mg methotrexate as sodium salt.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other excipients are: Sodium hydroxide and water for injections.</p><p>The solution has a pH of 7.0&ndash;8.5.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Clear, yellow concentrate for the preparation of a solution for infusion in vials.
Pack sizes:
Vials: 1 or 5 x 5 ml, 1 or 5 x 10 ml, 1 x 50 ml
Vials with/without transparent plastic containers (Onco-Safe).
Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>EBEWE Pharma Ges.m.b.H. Nfg. KG,</p><p>4866 Unterach,</p><p>Austria</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">عقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر هو دواء يتمتع بالخصائص الآتية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يثبط نمو بعض الخلايا التي تتكاثر بسرعة داخل الجسم (مادة فعالة لمكافحة السرطان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يقلل من التفاعلات العكسية لجهاز الدفاع الخاص بالجسم (كابت للمناعة)، و</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; له تأثير مضاد للالتهاب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستخدم عقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر في البالغين والمراهقين والأطفال من سن 3 أشهر (بمفرده للإعطاء داخل القراب، انظر قسم 3) وذلك وحده أو بمصاحبة علاجات أخرى لعلاج بعض أنواع السرطان، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السرطان المتعلق بالأمراض النسائية</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الثدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أورام الرأس والرقبة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجهاز الليمفاوي (سرطان الغدد الليمفاوية غير الهودجكين، سرطان الغدد الليمفاوية الذي يصيب الجهاز العصبي المركزي بشكل رئيسي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الدم (سرطان الدَّم اللمفاوي الحاد، سرطان الدم السحائي)</p><p dir="RTL">&nbsp;</p><p dir="RTL">عقار ميثوتريكسات إيبيفيه أقراص، عقار ميثوتريكسات إيبيفيه 20 مجم/مللي لتر محلول للحقن في سرنجات معبأة مسبقًا، عقار ميثوتريكسات إيبيفيه 10 مجم/مللي لتر محلول للاستخدام عن طريق الحَقْن أو عقار ميثوتريكسات إيبيفيه 10 مجم/مللي لتر محلول للحقن في سرنجات معبأة مسبقًا مناسب لعلاج الحالات الشديدة والمُعَممة من الصدفية المستعصية والتهاب المفاصل الصدفي والتهاب المفاصل الروماتويدي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم عقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر في الحالات الآتية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه ميثوتريكسات أو تجاه أي مكون من المكونات الأخرى بهذا الدَّواء المدرجة في قسم: 6.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من عدوى شديدة أو حادة أو مزمنة مثل السل أو فيروس نقص المناعة البشري &quot;HIV&quot;.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك التهاب في الغشاء المخاطي للفم أو كان لديك قرحة في تجويف الفم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك قُرح في منطقة المعدة/الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كلوي شديد (أو إذا قام طبيبك بتصنيف المرض على أنه خطير).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مرض كبدي شديد (أو إذا قام طبيبك بتصنيف المرض على أنه خطير).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض في جهاز تكوين الدم (على سبيل المثال: بعد العلاج الإشعاعي أو العلاج الكيميائي السابق)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من اضطرابات بالدَّم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإفراط في تناوُل الكحول، وأمراض الكبد الناجمة عن الكحول، أو غيرها من أمراض الكبد المزمنة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من أمراض نقص المناعة (ضعف أداء الجهاز المناعي للجسم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ مرضعًا (انظري قسم: &quot;الحمل والرضاعة والخصوبة&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملًا (ما لم يكن الطبيب قد قرر أنه مرض مهدد للحياة، انظري أيضًا قسم: &quot;الحمل والرَّضاعة الطبيعية والخصوبة&quot;)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا تم إعطاؤك لقاحات حيَّة في الوقت نفسه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">يجب أَلَّا يُوصف عقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر إِلَّا من قِبَل أطباءٍ ذوي خبرة كافية في علاج المرض المعني؛ بعقار ميثوتريكسات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>قبل العلاج</u></p><p dir="RTL">قبل بدء العلاج، سيقوم طبيبك بإجراء اختبارات دم، والتَّحقق من كفاءة عمل الكليتين والكبد. قد تخضع أيضًا لفحص بالأشعة السينية على الصدر. أثناء العلاج وبعده، قد يتم إجراء اختبارات إضافية. بالإضافة إلى الفحوصات المذكورة أعلاه، يمكن أيضًا إضافة فحوصات للفم والحلق في هذه المرحلة. قد يلزم إجراء الفحوصات بشكل أكثر تكرارًا إذا زادت الجرعة المخصصة لك. لا تفوت الحضور في مواعيدك الخاصة بإجراء اختبارات الدَّم والفحوصات الأخرى.</p><p dir="RTL">إذا كانت نتائج أيٍّ من الاختبارات غير طبيعية، لا يتم استئناف العلاج إلا بمجرد عودة جميع القيم إلى وضعها الطبيعي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لاحتمالية حدوث تفاعلات سُميَّة خطيرة (قد تكون مُميتة) أثناء علاج المرضى المُصابين بأورام، تم تخصيص عقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر للاستخدام في علاج المرضى المُصابين بأورام مُهَدِّدة للحياة فقط، بجرعات متوسطة ومرتفعة على وجه الخصوص. تم الإبلاغ عن حدوث حالات وفاة أثناء استخدام عقار ميثوتريكسات لعلاج أمراض الأورام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء العلاج بعقار ميثوتريكسات إيبيفيه100 مجم/ مللي لتر، يجب ملاحظتك عن كثب حتى يمكن اكتشاف أيِّ أعراض للتسمم بسرعة. في حالة وجود أعراض تسمم، يجب استشارة طبيب فورًا، والذي يقرر مراقبة وعلاج أعراض التسمم، بما في ذلك الفحوصات المعملية المنتظمة، ويبلغك بالمزيد من الإجراءات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُؤدي إيقاف العلاج بعقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر دائمًا إلى التعافي التَّام من الآثار الجانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>فحوصات المتابعة والتدابير الاحترازية الموصى بها</u><u>:</u></p><p dir="RTL">قد تحدث آثار جانبية شديدة حتى إذا تم إعطاء عقار ميثوتريكسات إيبيفيه100 مجم/ مللي لتر بجرعات منخفضة. يجب على طبيبك إجراء فحوصات واختبارات معملية؛ للكشف عنها في الوقت المناسب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>احتياطات خاصَّة للعلاج بعقار ميثوتريكسات إيبيفيه</u><u>100 </u><u>مجم</u><u>/ </u><u>مللي لتر</u></p><p dir="RTL">قد يكون لعقار ميثوتريكسات آثار مطفرة. يضعف عقار ميثوتريكسات إنتاج خلايا الحيوانات المنوية والبويضات مؤقتًا، وهو أمر قابل للارتداد في معظم الحالات. من الممكن أن يسبب عقار ميثوتريكسات حالات إجهاض وعيوب خلقية شديدة. يجب عليكِ وعلى زوجك تجنب حدوث الحمل أو منع إنجاب أطفال أثناء العلاج بعقار ميثوتريكسات ولمدة 6 أشهر على الأقل بعد انتهاء العلاج. انظري قسم: &quot;الحمل والرَّضاعة الطبيعية والخصوبة&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُرجى التحدُّث إلى طبيبك قبل استخدام عقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر في الحالات التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بمرض السكري الذي يتم علاجه بالأنسولين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى غير نشطة، مزمنة (مثل السل، التهاب الكبد من النوع &quot;بي&quot; أو &quot;سي&quot;، القوباء المنطقية [الهربس النطاقي]) أو الجدري المائي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت عُرضة لمسببات مرض الجدري المائي أو القوباء المنطقية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من عدوى نشطة أو مرض جلدي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أو قد كان لديك مرض في الكبد أو الكُلى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في وظائف الرئة، أو أصبت بالسعال أو ضيق النفس.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من زيادة الوزن على وجه الخصوص.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تراكُم غير طبيعي للسوائل في بطنك أو في التجويف الواقع بين الرئتين والجدار الصدري (استسقاء، انصباب بلوري).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الجفاف أو تعاني من حالات تسبب الجفاف (القيء والإسهال والتهاب الغشاء المخاطي للفم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لاحظت نزيفًا أو كدمات غير معتادة، وجود دم في البول أو بقع حمراء على الجلد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من قرح في المعدة أو إسهال أو قيء دموي، أو إذا كان البراز بلون أسود أو يحتوي على دم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى/ قد تلقيت العلاج الإشعاعي أو تتناول/ قد تناولت أدوية بإمكانها أن تلحق الضرر بالنخاع العظمي.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى تطعيمًا.&nbsp; يجب عدم إعطاء اللقاحات الحية (على سبيل المثال الحصبة، النكاف، الحصبة الألمانية) أثناء العلاج بعقار ميثوتريكسات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الجهاز المناعي أو تشعر بأنك لست على ما يُرام</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأمراض الجلدية</u></p><p dir="RTL">إذا كنت تعاني من مشاكل جلدية بعد العلاج الإشعاعي (التهاب الجلد النَّاجم عن الإشعاع (التهاب الجلد)) أو بعد حروق الشمس، فقد تحدث هذه الأعراض مرة أخرى مع العلاج بعقار ميثوتريكسات (تفاعل &quot;المعاودة&quot;).</p><p dir="RTL">قد تتفاقم التغييرات الجلدية الناجمة عن الصدفية أثناء العلاج بعقار ميثوتريكسات إيبيفيه إذا تعرضت للأشعة فوق البنفسجية في الوقت نفسه.</p><p dir="RTL">قد يسبب عقار ميثوتريكسات تفاعلات جلدية شديدة وأحيانًا تُؤدي إلى الوفاة والتي قد تحدث حتى بعد الإعطاء مرة واحدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>وظائف الكبد</u></p><p dir="RTL">قد يسبب عقار ميثوتريكسات التهاب الكبد وأمراض الكبد المزمنة والتي قد تُؤدي إلى الوفاة، ولا يحدث ذلك بشكل عام إلا بعد الاستخدام لفترة طويلة.</p><p dir="RTL">نظرًا لأنَّ عقار ميثوتريكسات قد يسبب تلف الكبد، يجب تجنب تناول/ استخدام الأدوية التي تهاجم الكبد أثناء العلاج. أثناء العلاج بعقار ميثوتريكسات، يجب تجنب تناوُل الكحوليات تمامًا.</p><p dir="RTL">في حالة حدوث أحد الأعراض التَّالية، يجب استشارة الطبيب فورًا: التهاب الغشاء المخاطي للفم، الإسهال، وجود دم في البراز، بقع سوداء في البراز، البلغم أو السعال المصحوب بدم أو القيء الدموي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>وظائف الرئة</u></p><p dir="RTL">يجب التَّوقف عن العلاج فورًا إذا كنت تعاني من السعال أو الحمى أو ضيق النفس أو ألم في الصدر أو إذا أُصبت بالتهاب في الرئة. من الممكن أن تحدث أمراض رئوية ناجمة عن ميثوتريكسات في أيِّ وقت أثناء العلاج ولا يمكن القضاء عليها دائمًا.</p><p dir="RTL">تم الإبلاغ عن نزيف الرئة الحاد في المرضى الذين يعانون من الأمراض الروماتيزمية الكامنة مع استخدام عقار ميثوتريكسات. اتصل بالطبيب فورًا إذا لاحظت وجود علامات بلغم أو سعال مُدمَّم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الجهاز العصبي</u></p><p dir="RTL">لُوحظت آثار جانبية خطيرة تُؤثر على المخ أو الجهاز العصبي، مثل الصداع والغيبوبة وأعراض الشلل والسكتة الدماغية، أثناء العلاج بعقار ميثوتريكسات. حدثت هذه الآثار الجانبية عادة في الأطفال والمراهقين الذين تلقوا عقار ميثوتريكسات بمصاحبة أحد علاجات الأورام (سيتارابين).</p><p dir="RTL">إذا تم حقن عقار ميثوتريكسات مباشرة في الحيز تحت العنكبوتية (نظام التَّجويف بالجهاز العصبي المركزي، داخل القراب)، فسيتم وضعك تحت الملاحظة تحسبًا لظهور علامات الإصابة بسُمية عصبية (تلف في الجهاز العصبي، على سبيل المثال: تهيُّج السحايا، الشلل المؤقت أو الدائم، أمراض المخ).</p><p dir="RTL">لوحظ أثناء العلاج بجرعات عالية من ميثوتريكسات حدوث متلازمات عصبية حادة ومؤقتة مصحوبة بأعراض مثل الاضطرابات السلوكية أو ردود الأفعال غير الطبيعية أو أعراض حسية حركية بؤرية (تشمل فقدان البصر المؤقت).</p><p dir="RTL">في المرضى من الأطفال المُصابين بسرطان الدَّم اللمفاوي الحاد، قد يحدث تلف شديد في الجهاز العصبي (سُمية عصبية) بعد العلاج بجرعات عالية بشكل معتدل من عقار ميثوتريكسات الذي يتم إعطاؤه عن طريق الوريد، الأمر الذي تم الإبلاغ عنه بشكل شائع في صورة نوبات صرع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الأورام</u></p><p dir="RTL">تم الإبلاغ عن تغييرات باثولوجية في المادة البيضاء بالمخ من قِبل المرضى، ولا يمكن استبعاد أمراض أخرى في المخ.</p><p dir="RTL">في بعض الأحيان، تم الإبلاغ عن حدوث إصابة بسرطان الغدد الليمفاوية الخبيثة مع استخدام جرعة منخفضة من عقار ميثوتريكسات، والذي تم انحساره/تراجعه في بعض الحالات بعد إيقاف العلاج بعقار ميثوتريكسات.</p><p dir="RTL">في المرضى المُصابين بأورام سريعة النمو، قد يُسبب عقار ميثوتريكسات اضطرابات استقلابية.</p><p dir="RTL">في حالة الإصابة بسرطان الدَّم اللمفاوي الحاد، قد يحفز عقار ميثوتريكسات الألم في النَّاحِيَة الشُّرْسوفِيَّة اليسرى (بسبب التهاب في الـمِحفظة الطحاليَّة).</p><p dir="RTL"><br /><strong>تناوُل عقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر مع أدوية أخرى</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي الخاص بك إذا كنت تتناول/ تستخدم أو تناولت/ استخدمت مؤخرًا أو قد تتناول/ تستخدم أيَّة أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن أن يُؤدي استخدام عقار ميثوتريكسات بالتَّزامن مع أدوية أخرى إلى تعزيز أو إضعاف متبادل للتأثير، أو ربما تفاقم الآثار الجانبية، وقد يُسبب أضرارًا جسدية خطيرة في ظروف معينة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تذكر أن تخبر طبيبك حول العلاج بعقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر إذا تم وصف دواء آخر لك أثناء العلاج. إذا وُصفت الأدوية من قِبل أطباء آخرين لعلاج الأمراض الأخرى، فيجب دائمًا إبلاغ الطبيب الذي يراقب العلاج بعقار ميثوتريكسات بهذا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من المهم بشكل خاص أن تخبر طبيبك إذا كنت تتناول/ تستخدم أيًّا من العقاقير التَّالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقاقير أخرى لعلاج التهاب المفاصل الروماتويدي أو الصدفية، مثل: لفلونوميد، أو سلفاسالازين (يتم إعطاؤها أيضًا لعلاج التهاب القولون التقرحي)، الأسبرين، (حمض أسيتيل الساليسيليك)، فينيل بوتازون أو أميدوبيرين (مشتقاتها)، مركبات الذهب، بنسيلامين، هيدروكسي كلوروكوين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير السترويدية (بعض الأدوية المسكنة للألم والمضادة للالتهابات). يجب توخي الحذر بشكل خاص، حيث توجد حالات إبلاغ عن آثار جانبية خطيرة، بما في ذلك حدوث الوفاة، فيما يتعلق بهذه العقاقير.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الساليسيلات (مسكنات ذات تأثيرات مسكنة للألم وخافضة للحرارة ومضادة للالتهابات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكحوليات (يجب تجنب تناولها).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اللقاحات (الحية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزاثيوبرين (للوقاية من رفض الجسم للعضو المزروع بعد الزرع).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرتينويدات (لعلاج الصدفية وغيرها من الأمراض الجلدية)، مثل إيتريتينيت</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات التشنجات (مثل فينيتوين، ليفيتيراسيتام؛ الأدوية المستخدمة لعلاج نوبات التشنج)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية علاج السرطان (مثبطات نمو الخلايا مثل سِيسْبلاتين، بروكاربازين، ال- اسباراجيناز، فلورويوراسيل 5، دوكسوروبيسين، فينكريستين، 6-مركابتوبورين، بليوميسين أو سيتارابين).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تريامتيرين (دواء مُدر للبول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الباربيتورات (أدوية علاج الصرع وأدوية التخدير).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية التخدير القائمة على أكسيد النيتروجين (أكسيد النيتروز؛ يرجى التَّحدث إلى طبيبك إذا كنت بصدد الخضوع لعملية جراحية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المهدئة (المهدئات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حبوب منع الحمل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بروبينيسيد (لعلاج النقرس).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية مثل: البنسيلين، السالفوناميدات، سيبروفلوكساسين، بريستينامايسين، التتراسيكلينات، كلورامفينيكول، كوترايموكسازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بيريميثامين (للوقاية من الملاريا وعلاجها).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; منتجات (مشتقات) الفيتامينات التي تحتوي على حمض الفوليك أو حمض الفولينيك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي يمكنها أن تسبب نقصًا في حَمْض الفوليك.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات مضخة البروتون (بما في ذلك علاج الحموضة (حُرْقَة الفُؤاد) الشديدة أو القرح الشديدة)، مثل لانسوبرازول، أوميبرازول أو بانتوبرازول.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثيوفيلين (بما في ذلك علاج الربو).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أميودارون (لعلاج اضطرابات النظم القلبي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات تجلط الدَّم الشبيهة بالكومارين (أسِينُوكُومارُول، فينوبروكومون).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميتاميزول (لعلاج الألم الشديد والحمى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض بارا أمينوبنزويك (على سبيل المثال باعتباره أحد مكونات أدوية التخدير الموضعية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض بارا أمينوهيبوريك (يُستخدم في فحص وظائف الكُلى).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الكورتيكوستيرويدات (&quot;الكورتيزون&quot;) (لعلاج الأمراض الالتهابية وأمراض الحساسية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولستيرامين (لعلاج ارتفاع قيم الكوليسترول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كرات الدم الحمراء المكدسة (لعمليات نقل الدَّم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأحماض العضوية الضعيفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من الممكن زيادة خطر حدوث نخر الأنسجة الرخوة، أو نخر العظام (موت الأنسجة الرخوة أو العظمية)، مع العلاج الإشعاعي أثناء استخدام عقار ميثوتريكسات.</p><p dir="RTL">قد يتعرَّض المرضى الذين يتلقون بعد ذلك عمليات نقل دم خلال 24 ساعة من تسريب عقار ميثوتريكسات لزيادة احتمالية حدوث تسمم بسبب الارتفاع المستمر لتركيزات عقار ميثوتريكسات في مصل الدم بشكل مطول.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>استخدام ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر مع الطعام والشراب والكحوليات</strong></p><p dir="RTL">يجب عدم تناوُل الكحوليات أثناء العلاج بعقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر ويجب تجنب الإفراط في تناوُل القهوة والمشروبات الغازية التي تحتوي على الكافيين والشاي الأسود.</p><p dir="RTL">تأكد من تناول كمية كبيرة من السوائل أثناء العلاج باستخدام عقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر؛ نظرًا لأنَّ الجفاف (انخفاض نسبة الماء في الجسم) قد يزيد من سمية عقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرَّضاعة الطبيعية والخصوبة</strong></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا تستخدمي عقار ميثوتريكسات إيبيفيه أثناء الحَمْل إذا لم يصفه لكِ طبيبكِ لعلاج الأورام. من الممكن أن يسبب عقار ميثوتريكسات عيوبًا خِلقية أو يضر بالجنين أو يحفز على الإجهاض. فهو يصاحبه تشوهات بالجمجمة والوجه والقلب والأوعية الدَّموية والمخ والأطراف. لذلك، يُعد عدم إعطاء عقار ميثوتريكسات للسيدات الحوامل أو المريضات اللاتي يعتزمن الحمل أمرًا هامًّا، إلا إذا كان سيتم استخدامه لعلاج الأورام.</p><p dir="RTL">في حال الاستخدام لدواعي غير علاج الأورام، يجب استبعاد حدوث حَمْل لدى السيدات ممن هن في سن الإنجاب باستخدام وسائل منع الحَمْل المناسبة قبل بدء العلاج، مثل إجراء اختبار حَمْل،</p><p dir="RTL">لا تستخدمي عقار ميثوتريكسات إيبيفيه إذا كنت تعتزمين الحمل. يجب عليكِ تجنب الحمل أثناء استخدام عقار ميثوتريكسات ولمدة ستة أشهر على الأقل بعد انتهاء العلاج. لذا، يجب عليكِ التَّأكد من استخدام وسيلة موثوقة لمنع الحَمْل (على سبيل المثال، وسائل منع الحمل عن طريق الفم مثل &quot;حبوب منع الحَمْل&quot;) طوال هذه الفترة (انظري أيضًا القسم: &quot;تحذيرات واحتياطات&quot;).</p><p dir="RTL">إذا أصبحتِ حاملًا أثناء العلاج أو اشتبهت في أنك قد تكونين حاملًا، فاتصلي بطبيبك في أسرع وقت ممكن. إذا أصبحتِ حاملًا أثناء العلاج، يجب إبلاغك بما يتعلق بخطر الآثار الضارة على الطفل أثناء العلاج.</p><p dir="RTL">إذا كنت ترغبين في حدوث حمل، فيجب استشارة طبيبك الذي بإمكانه إحالتك إلى أخصائي قبل البداية المقررة للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">لا تمارسي الرضاعة الطبيعية أثناء العلاج لأنَّ عقار ميثوتريكسات يمر إلى لبن الأم. إذا كان الطبيب المعالج يرى أن العلاج بعقار ميثوتريكسات أثناء فترة الرضاعة أمر لا مفر منه، فيجب عليكِ عدم ممارسة الرضاعة الطبيعيَّة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>القدرة الإنجابية لدى الذكور</u></p><p dir="RTL">لا تشير البيانات المتاحة إلى زيادة خطر حدوث تشوهات أو حالات إجهاض إذا تم علاج الأب أسبوعيًّا بجرعة أقل من 30 مجم من عقار ميثوتريكسات. مع ذلك، لا يُمكِن استبعاد وجود مخاطر استبعادًا تامًّا ولا توجد معلومات بشأن استخدام عقار ميثوتريكسات بجرعات أعلى. قد يكون لعقار ميثوتريكسات تأثير سام للأجنة. يعني ذلك أنَّ الدواء قد يُسبب تغييرات جينية. من الممكن أن يكون لعقار ميثوتريكسات تأثير سلبي على إنتاج الحيوانات المنوية مع احتمالية التسبب في إحداث عيوب خلقية. لذلك، يجب عليك تجنب إحداث الحمل أو التبرع بالحيوانات المنوية أثناء العلاج بعقار ميثوتريكسات ولمدة 6 أشهر على الأقل بعد نهاية العلاج. نظرًا لأنَّ العلاج المعتاد بعقار ميثوتريكسات لعلاج الأمراض السرطانية من الممكن أن يُؤدي إلى العقم وحدوث طفرات جينية، فقد يكون من المستحسن للمرضى الذكور الذين يخضعون للعلاج بجرعات تتجاوز 30 مجم/ الأسبوع التفكير في حفظ الحيوانات المنوية قبل بدء العلاج (انظر أيضًا قسم: &quot;التحذيرات والاحتياطات&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>قيادة المركبات وتشغيل الآلات</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Title: Warndreick - Description: Symbol: Achtung" style='width:30.75pt;
 height:27pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQCxgme2CgEAABMCAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbJSRwU7DMAyG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">
 <v:imagedata src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image001.png"
  o:title="" cropright="-320f"/>
</v:shape><![endif]--><img width="41" height="36" alt="Title: Warndreick - Description: Symbol: Achtung" src="file:///C:/Users/abulase1/AppData/Local/Temp/3/msohtmlclip1/01/clip_image002.gif" />تنبيه: قد يُضعف هذا الدَّواء من القدرة على التفاعل والقدرة على القيادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">أثناء العلاج بعقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر، قد يعاني الجهاز العصبي المركزي من آثار جانبية مثل الإرهاق أو نوبات الدوخة. لذلك، قد تتأثر القدرة على القيادة واستخدام الآلات في بعض الحالات. إذا شعرت بتعب أو دوخة، فتجنب القيادة أو استخدام الآلات. هذا صحيح بشكل خاص إذا كنت تتناول الكحول أثناء العلاج بعقار ميثوتريكسات إيبيفيه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي عقار ميثوتريكسات إيبيفيه 100 مجم/ مللي لتر على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مللي مول صوديوم (23 مجم) لكل زجاجة، أي أنه &quot;خال من الصوديوم&quot; بشكل أساسي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عدم وصف عقار ميثوتريكسات إيبيفيه 100مجم/ مللي لتر إلا من قِبل الأطباء الذين لديهم دراية بالخصائص المختلفة للدواء وطريقة عمله.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الجرعة الخاصة بأمراض الأورام</u></p><p dir="RTL">سيقرر طبيبك الجرعة اللازمة لك وفقًا لمرضك والحالة العامة وعدد خلايا الدَّم لديك. <strong>يجب الالتزام بهذه الجرعة التزامًا صارمًا</strong><strong>.</strong></p><p dir="RTL">من الممكن أن يُؤدي الاستخدام غير الصحيح لعقار ميثوتريكسات إيبيفيه إلى حدوث آثار جانبية شديدة وقد تؤدي إلى الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>طريقة ومدة الإعطاء</u><u>:</u></p><p dir="RTL">للاستخدام عن طريق العضل أو الوريد أو داخل الشريان أو داخل القراب أو داخل البطين.</p><p dir="RTL">يُمكِن إعطاء عقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر في العضل وفي الوريد وفي أحد الشرايين وفي العمود الفقري (داخل القراب) وفي بطينات المخ (داخل البطين).</p><p dir="RTL">يتم تحديد مدة العلاج من قِبل الطبيب المعالج.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الاستخدام في الأطفال والمراهقين وكبار السن </u></p><p dir="RTL">تعتمد تعليمات الجرعة على وزن جسم المريض. لا يوصى بالإعطاء للأطفال دون سن 3 سنوات من العمر (ماعدا فيما يخص الحقن داخل القراب)؛ حيث إنه لا توجد هناك بيانات كافية لهذه الفئة العمرية.</p><p dir="RTL">يجب مراقبة الأطفال والاشخاص من كبار السن (ممن تتجاوز أعمارهم 55 عامًا) بشكل خاص الذين يتم علاجهم بعقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر عن كثب، من أجل الكشف عن الآثار الجانبية المحتملة في أقرب وقت ممكن.</p><p dir="RTL">نظرًا لانخفاض وظائف الكبد والكلى، فضلًا عن انخفاض احتياطي الفولات لدى المرضى من كبار السن، يجب اختيار جرعة منخفضة نسبيًّا للمرضى من كبار السن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تلقيت كمية أكثر مما يجب من عقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر</strong></p><p dir="RTL">إذا كنت تشتبه في أنه قد تم إعطاؤك كمية أكثر مما يجب من عقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر، فأبلغ الطبيب فورًا. سيقرر الطبيب أيَّ التدابير العلاجية ضروريًّا بناءً على شدة التسمم.</p><p dir="RTL">يمكن أن تُؤدي جرعة زائدة من عقار ميثوتريكسات إلى حدوث أعراض سمية شديدة. قد تتضمن أعراض الجرعة الزَّائدة زيادة القابلية لحدوث النزيف أو الإصابة بالنزيف، وضعفًا غير معتاد، وتقرحات بالفم، والغثيان، والقيء، وخروج براز أسود أو مدمم، وسعالًا مصحوبًا بدم أو قيئًا دمويًّا ذا مظهر شبيه بالبُن المطحون، وقلة البول. بعد تلقي جرعة زائدة في القناة الفَقْريّة، تحدث أعراض الجهاز العصبي المركزي مصحوبة بشكل عام بحالات من الصداع والغثيان والقيء والنوبات التشنُّجية أو الاختلاجات واختلال حاد في وظائف المخ (اعْتِلَال دِماغِيّ تسممي). &nbsp;انظر أيضًا قسم: 4&quot;الآثار الجانبية المحتملة&quot;فولينات الكالسيوم هي الترياق في حال الجرعة الزائدة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>معلومات للطبيب</u><u>:</u> للاطلاع على معلومات حول الجرعات الزَّائدة، يُرجى الرجوع إلى نهاية هذه النَّشرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن استخدام عقار ميثوتريكسات إيبيفيه</strong></p><p dir="RTL">لا يجب قطع العلاج بعقار ميثوتريكسات إيبيفيه أو وقفه إلا بعد أن يقرر طبيبك ذلك. يجب أن تتصل بطبيبك على الفور لاستشارته إذا اشتبهت في وجود آثار جانبية خطيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدَّواء، استشر طبيبك أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل كافة الأدوية، قد يُسبب هذا الدَّواء آثارًا جانبية، على الرَّغم من عدم حدوثها لدى الجميع. من الممكن أن تكون العديد من هذه الآثار الجانبية شديدة، أو حتى تسبب الوفاة (المفاجئة).</p><p dir="RTL">لذلك، سيقوم الطبيب بإجراء فحوصات على الكلى أو الكبد؛ لتحديد أيِّ تغيرات في الدم (مثل انخفاض عدد خلايا الدَّم البيضاء، انخفاض قيم الصفائح الدَّموية وخلايا الغدد الليمفاوية)</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أبلغ الطبيب فورًا</strong> إذا واجهت الشكاوى التَّالية؛ حيث إنها تشير إلى وجود آثار جانبية خطيرة ومن المحتمل أن تكون مهددة للحياة ويجب علاجها على الفور. قد يقرر طبيبك خفض جرعة عقار ميثوتريكسات أو إيقاف علاجك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أزيز بالصدر، ضيق النفس، تورم في الجفون أو في الوجه أو في الشفتين، وكذلك الطفح الجلدي أو الحكة (خاصةً التي تتعلق بالجسم بالكامل)؛ لأنَّ هذه قد تكون علامات على حدوث تفاعل حساسية شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شكاوى بالرئة بما في ذلك الالتهاب الرئوي (تشمل الأعراض: شعورًا عامًّا بالإعياء، سعالًا جافًّا، ضيق النفس، ضيق النَّفس أثناء الرَّاحة، توقف التنفس، ألمًا بالصدر، أو حمى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال أو بلغم دموي (تم الإبلاغ عنهما نتيجة استخدام عقار ميثوتريكسات لعلاج مرض روماتيزمي كامن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مثل: الحمى، التهاب الحلق، قرح بالفم، شعور عام بالتوعك والإنهاك الشديد، نزيف من الأنف (رعاف)، أو وجود بقع حمراء صغيرة على الجلد قد تكون علامات على عدم أداء النخاع العظمي لوظائفه على النحو الصحيح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور نفطات على الجلد أو تقشره بشكل خطير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف (يشمل تقيؤ دم) أو كدمات بشكل غير طبيعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال شديد (خاصةً في غضون الـ 24-48 ساعة الأولى بعد إعطاء عقار ميثوتريكسات)، مضاعفات شديدة في الجهاز الهضمي (تضخم القولون التسممي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز أسود أو له لون القطران.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم بالبول أو البراز.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد (يرقان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو صعوبات عند التبول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عطش و/أو تكرار التبول.&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان البصر العابر، فقدان الرؤية، عدم وضوح الرؤية أو ضعف الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القيء وفقدان وظائف العضلات (على سبيل المثال: عدم القدرة على الحركة)؛ حيث إنَّ هذه قد تكون علامات على التِهاب السّحَايَا (التهاب المخ).</p><p dir="RTL">&nbsp;</p><p dir="RTL">فيما يلي بعض الآثار الجانبية الأخرى التي يمكن أن تحدث:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا</strong> (قد تُؤثر على أكثر من شخص واحد من بين كل 10&nbsp;أشخاص تم علاجهم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في تكوُّن خلايا الدَّم مع انخفاض في تعداد خلايا الدَّم البيضاء (قلة خلايا الدم البيضاء) و/ أو الصفائح الدَّموية (نقص الصَّفائح الدَّموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، ألم في البطن، إسهال (بشكل رئيسي خلال 24&ndash;48 ساعة الأولى بعد اعطاء ميثوتريكسات)، غثيان، قيء، التهاب وتقرح الأغشية المخاطية في الفم والحلق (بشكل رئيسي خلال 24&ndash;48 ساعة الأولى بعد اعطاء ميثوتريكسات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيم غير طبيعية في نتائج اختبارات الدَّم لوظائف الكبد (ارتفاع في أنزيمات الكبد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض معدل ترشيح الكلى (يمكن تحديده عن طريق اختبار من قِبل الطبيب ويبين تدهور وظائف الكلى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إنهاك، الشعور بالضيق(تَوَعُّك).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10&nbsp;أشخاص تم علاجهم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; القوباء المنطقية (الهربس النطاقي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في تعداد خلايا الدَّم الحمراء (فقر الدَّم)، تلف بالنخاع العظمي، والذي من الممكن أن يؤدي إلى هبوط شديد في تعداد خلايا الدَّم البيضاء (ندرة خلايا المحببات) أو خلايا الدم الشاملة (قلة الكريات الشاملة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نعاس، شعور بعدم الراحة/ وخز (اضطرابات الإحساس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب المُلْتَحِمَة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضاعفات بالرئة ناجمة عن الالتهاب الرئوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، احمرار الجلد، حكة، زيادة حساسية الجلد في ضوء الشمس (حساسية تجاه الضوء)، قرح بالجلد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 100 شخص تم علاجهم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى نتيجة لضعف تفاعل جهاز المناعة والذي يمكن أن يُؤدي إلى الوفاة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأورام الخبيثة في الأنسجة الليمفاوية (الأورام الليمفاوية الخبيثة)، والتي تراجعت في بعض الحالات بعد إيقاف العلاج بميثوتريكسات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية من خلال صدمة تحسسية، زيادة في العدوى/ الالتهابات الناجمة عن كبت الجهاز المناعي للجسم (كبت المناعة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض السُّكَّرِي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شلل بجانب واحد (خَزَلٌ شِقِّيّ)، ارتباك/ التباس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب بالأوعية الدموية، التهاب الأوعية الدَّموية التحسسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تحول الأنسجة الضامة في أنسجة الرئة (التليف الرئوي)، تراكم السوائل بين الأغشية الرئوية (انصباب بلوري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قُرح ونزيف في الجهاز الهضمي، التهاب البنكرياس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الكبد (سمية كبدية)، الكبد الدهني، تكوين نسيج ندبي في الكبد (تليف الكبد)، تحول أنسجة الكبد مع تندُّب وانخفاض في وظائف الكبد (تليُّف الكبد)، انخفاض في ألبومين مصل الدَّم (وجود بروتين في الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات جلدية شديدة ومهددة للحياة (متلازمة ستيفنز جونسون، متلازمة لايل، أعراض جلدية شبيهة بالحمى)، تورمات حمراء اللون على الجلد (أرتكاريا)، زيادة تصبغ الجلد، إصابات جلدية مؤلمة تحت الجلد (عُقيدات)، إصابات جلدية مؤلمة في الصدفية، اضطرابات التئام الجروح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم بالمفاصل، ألم عضلي، انخفاض كتلة العظام (هشاشة العظام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض كلوية شديدة، فشل كُلوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وقروح في المثانة، اضطرابات بإفراغ المثانة، انخفاض أو عدم إنتاج البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوهات بالأجنة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب وقرح في منطقة المهبل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمَّى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع استخدام عقار ميثوتريكسات عن طريق العضل، قد تحدث آثار جانبية موضعية (إحساس بالحُرقة) أو تلف (تكوُّن خراجات عقيمة، تلف بالنسيج الدهني) في موضع إعطاء العقار</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة </strong>(قد تُؤثر على ما يصل إلى شخص واحد من بين كل 1000 شخص تم علاجهم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تسمم دموي (تعفن الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب نمو ونضوج خلايا الدم الحمراء مع فقر الدم (فقر الدم ضخم الأرومات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقلبات الحالة المزاجية، اضطرابات إدراكية عابرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; شلل، اضطرابات بالكلام، تغييرات باثولوجية في المادة البيضاء بالمخ (اعْتِلال بيضاء الدماغ).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات الرؤية (شديدة جزئيًّا)، انسداد الأوردة على الشبكية (جلطة بشبكية العين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم، انسداد الأوعية الدموية عن طريق جلطات الدَّم في الأوردة والشرايين (تخثر الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في منطقة الحلق، توقف التنفس، انصمام رئوي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجهاز الهضمي، براز مُدمَّم، التهاب اللثة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد الحاد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب، نزيف بالجلد على شكل نقطة أو منطقة صغيرة، التهاب الجلد (احمرار متعدد الأشكال)، طفح جلدي أحمر، زيادة تصبغ الأظافر، انفصال الأظافر من فِراش الظُّفُر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسور بالعظام بسبب الضغط.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع اليوريا والكرياتينين وحمض اليوريك في الدَّم، وزيادة في المنتجات الاستقلابية التي تحتوي على النيتروجين في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإجهاض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد الحيوانات المنوية واضطرابات دورة الطمث لدى الإناث، والتي تتراجع مع ذلك بعد نهاية العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا</strong> (قد تُؤثر على ما يصل إلى شخص واحد من بين كل 10000 شخص تم علاجهم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد النَّاجم عن فيروسات الهربس (التهاب الكبد النَّاجم عن الهربس البسيط)، عدوى ناجمة عن الفطريات (داء النَّوسَجات، داء المستخفيات)، وناجمة عن البكتيريا (داء النوكارديات)، وناجمة عن الفيروسات (عدوى الفيروس المضخم للخلايا، بما في ذلك الالتهاب الرئوي)، الهربس البسيط واسع الانتشار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقر الدَّم (فقر الدَّم اللاتنسجي)، ارتفاع في بعض خلايا الدَّم البيضاء (كثرة خلايا اليُوزينِيَّات)، انخفاض في بعض خلايا الدَّم البيضاء (قلة خلايا العَدِلات)، تورم العقد الليمفاوية، مرض لمفي تكاثري (نمو مفرط لبعض خلايا الدَّم البيضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الأجسام المضادة في الدَّم (نقص جاما جلوبولين الدَّم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات وألم في الأطراف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بطعم معدني بالفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الجلد الدماغي والذي يصاحبه حدوث شلل أو قيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم حول تجويف العين، التهاب جفن العين، تدفق الدموع، زيادة حساسية العين تجاه الضوء، فقدان البصر المؤقت، فقدان الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب التأمور، إعاقة ملء القلب نتيجة وجود انصباب في التأمور (اندكاك التأمور)، تراكم السوائل بين أغشية التأمور (انصباب تأموري).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض مزمن في أنسجة الرئة، تفاعلات شبيهة بالربو مع السعال، صعوبة في التنفس، نتائج غير طبيعية بعد اختبار وظيفة الجهاز التنفسي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقيؤ دم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت خلايا الكبد (نخر الكبد الحاد)، تلف الكبد، فشل الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى العميقة لجريبات الشعر (دُمال)، تمدد مرئي دائم للشعيرات الدموية (توسع الشعيرات)، التهاب فِراش الظُّفُر وطَيَّة الظُّفُر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البول، زيادة إفراز البروتين مع البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب غدد إفراز العرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوه خلايا البويضة أو الحيوانات المنوية، العُقم، اضطرابات دورة الطمث، فقدان الاهتمام الجنسي (فقدان الرغبة الجنسية)، عُنَّة (اضطرابات الانتصاب)، الإفرازات المهبلية، تضخم الثدي لدى الرجال (التثدي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تحمل اعطاء عقار ميثوتريكسات أسفل الجلد تحملًا موضعيًّا جيدًا. ولم تلاحظ سوى تفاعلات جلدية بسيطة، وكانت تخف أثناء العلاج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتنميل أو الوخز/انخفاض الإحساس عند اللمس عن المعتاد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل التكرار من واقع البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي، معاودة الإصابة بعدوى التهاب الكبد من النوع &quot;بي&quot;، تفاقم عدوى التهاب الكبد من النوع &quot;سي&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب تجويف البطن، مضاعفات شديدة في الأمعاء الغليظة (تضخم القولون السُّمي)، انثقاب الأمعاء، التهاب اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف بالجهاز العصبي (سُمية عصبية)، التهاب أحد الأغشية الدماغية (التهاب العنكبوتية)، فقدان الإحساس وحركة الساقين (الشلل السفلي)، تيبُّس الجسم بأكمله (خِدر)، اضطراب في التسلسل المنظم وتنسيق حركات العضلات (ترنح)، الخرف، زيادة الضغط في السائل الشوكي في المخ (السائل النخاعي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر، نقص الأكسجين في الأنسجة (نقص الأكسجين بالدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف رئوي (تم الإبلاغ عنه نتيجة استخدام عقار ميثوتريكسات لعلاج مرض روماتيزمي كامن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل دوائي مع طفح جلدي على كامل الجسم وزيادة الحمضات (نوع معين من خلايا الدَّم البيضاء) في الدَّم (ما يسمى بمتلازمة الطفح الجلدي الدَّوائي المصحوب بكثرة خلايا اليُوزينِيَّات والأعراض الجهازية)، التهاب الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; موت أنسجة العظم (على سبيل المثال: نخر في عظام الفك).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور في وظائف أعضاء الجهاز البولي والأعضاء الجنسية (قصور وظائف الجهاز البولي التناسلي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأنسجة في موضع الحقن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار وتقشر الجلد (ظهور حراشف عليه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتعاش.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يؤدي أيضًا استخدام عقار ميثوتريكسات <strong>داخل القراب وعن طريق الوريد</strong> إلى التهاب حاد في المخ وتغيُّرات باثولوجية حادة في المخ تؤدي إلى الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عند إعطاء العقار داخل القراب، قد يحدث تلف في الجهاز العصبي المركزي قد يتجلى في صور مختلفة كالآتي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الغشاء العنكبوتي الدماغي (التهاب العنكبوتية) (مع أعراض تشمل على سبيل المثال، صداعًا وألمًا بالظهر وتيبُّس الرقبة وحُمَّى).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب النُّخاعِ الشوكي (مع أعراض تشمل على سبيل المثال، شلل الأطراف غير الكامل، الشلل السفلي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيُّرات باثولوجية مُزمِنة في المادة البيضاء بالدماغ (اعتلال بيضاء الدماغ) (مع أعراض تشمل على سبيل المثال، ارتباكًا وهياجًا ونعاسًا وترنحًا وخرفًا ونوبات تشنجية وغيبوبة). قد يستمر هذا التلف في التدهور ويؤدي إلى الوفاة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هناك دليل على أن استخدام العلاج الإشعاعي بالجمجمة وعقار ميثوتريكسات داخل القراب بالتزامن يزيد من نسبة حدوث اعْتِلال بَيضاءِ الدِّماغِ (تغييرات باثولوجية بالمادة البيضاء بالمخ). بعد تلقي العقار داخل القراب يجب عليك الخضوع للمراقبة تحسبًا لظهور علامات مُحتَمَلة تُشير إلى الإصابة بتلف عصبي (تهيُّج الأغشية الدماغية، شلل مؤقت أو دائم، تغيُّرات باثولوجية في المخ).</p><p dir="RTL">&nbsp;</p><p dir="RTL">وردت تقارير بشأن المرضى المُصابين بسرطان الغدد اللمفاوية في الجهاز العصبي المركزي حيث أدى استخدام عقار ميثوتريكسات داخل القراب إلى حدوث تحولات في أجزاء من الدماغ لديهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يعاود التهاب الجلد الناجم عن الإشعاع وحروق الشمس الظهور نتيجة استخدام عقار ميثوتريكسات (تُسمى تفاعلات &quot;المعاودة&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يخفض ميثوتريكسات من عدد خلايا الدَّم البيضاء وبالتالي يضعف جهاز المناعة.&nbsp; إذا واجهت أعراض العدوى، مثل الحُمَّى أو تفاقم شديد في حالتك العامة، أو حُمَّى مع علامات موضعية للعدوى، مثل ألم بالحلق/ التهاب الحلق أو الفم، أو مشاكل في التبوُّل، فاستشر طبيبك فورًا.</p><p dir="RTL">سيُجرى اختبار دم للكشف عن حدوث انخفاض مُحتَمَل في خلايا الدَّم البيضاء. من المُهِم إبلاغ طبيبك بشأن أدويتك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفَظ في درجة حرارة أقل من 25 درجة مئوية.</p><p dir="RTL">يخزن في العبوة الأصلية للحماية من الضوء.</p><p dir="RTL">يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدَّواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الكرتونيَّة أو الملصق بعد كلمة &quot;EXP&quot;. يشير تاريخ الصلاحية إلى آخر يوم من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب استخدام المنتج الدوائي فور فتحه.</p><p dir="RTL">يجب ألا تستخدم عقار ميثوتريكسات إيبيفيه 100 مجم/مللي لتر إذا لم يكن المحلول صافيًا ويحتوي على جسيمات. للاستخدام مرة واحدة فقط. يجب التَّخلص من أي منتج لم يتم استخدامه.</p><p dir="RTL">يجب التَّخلص من أي أدوية لم يتم استخدامها أو أية مخلفات وفقًا للوائح الوطنية للمواد السامة للخلايا.</p><p dir="RTL">يجب تجنُّب ملامسة المحلول للجلد أو الأغشية المخاطية.</p><p dir="RTL">يجب على أخصائيي الرعاية الصحية الذين يتعاملون مع الحوامل عدم لمس عقار ميثوتريكسات أو إعطائه.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي ميثوتريكسات. يحتوي كل مللي لتر على 100 مجم ميثوتريكسات في هيئة أملاح الصوديوم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السواغات الأخرى هي: هيدروكسيد الصوديوم، ماء للحقن.</p><p dir="RTL">للمحلول درجة حموضة تتراوح بين 7.0 و8.5.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مُركَّز صافٍ وأصفر اللون لإعداد محلول للتَّسريب مُعبأ في زجاجات.</p><p dir="RTL"><u>أحجام العبوات</u><u>:</u></p><p dir="RTL">الزجاجات: 1 أو 5 &times; 5 مللي لترات، 1 أو 5 &times; 10 مللي لترات، 1 &times; 50 مللي لترًا</p><p dir="RTL">زجاجات مع/بدون حاويات بلاستيكية شفافة (Onco-Safe).</p><p dir="RTL">قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة إيبيفيه فارما المحدودة Nfg.KG</p><p dir="RTL">4866 أونتراخ،</p><p dir="RTL">النمسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Methotrexat “Ebewe” 100 mg/ml – concentrate for the preparation of an infusion solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 ml contains 100 mg methotrexate as a sodium salt in an aqueous solution. 

Excipients with known effect: 
1 ml contains 17.62 mg sodium hydroxide in an aqueous solution. 

The solution has a pH of 7.0–8.5. 
Osmolality: 440 mOsm/l Na+.

For the full list of excipients, see Section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Clear, yellow concentrate for the preparation of an infusion solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Methotrexat &ldquo;Ebewe&rdquo; 100&nbsp;mg/ml is used in adults, adolescents and children 3 months of age and older (solely intrathecal administration, see Section 4.2 b)).</strong></p><p><strong>&nbsp;</strong></p><p><strong>Methotrexat &ldquo;Ebewe&rdquo; in a low (single dose &lt;100&nbsp;mg/m<sup>2 </sup>body surface area [BSA]) and medium dosage (single dose 100&ndash;1000&nbsp;mg/m<sup>2 </sup>BSA) is indicated in the following oncological diseases:</strong></p><p>&nbsp;</p><p>Malignant trophoblastic tumours (bladder moles, chorionepithelioma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As mono-chemotherapy in female patients with a favourable prognosis (&ldquo;low risk&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In combination with other cytostatic medicinal products in female patients with an unfavourable prognosis (&ldquo;high risk&rdquo;)</p><p>&nbsp;</p><p>Breast cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In combination with other cytostatic medicinal products as adjuvant therapy following resection of the tumour or mastectomy and as palliative therapy at an advanced disease stage</p><p>&nbsp;</p><p>Tumours in the head and neck area</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For palliative monotherapy in the metastatic stage or with relapses</p><p>&nbsp;</p><p>Non-Hodgkin&rsquo;s lymphoma</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For treatment of intermediate or high-grade non-Hodgkin&rsquo;s lymphoma in combination with other cytostatic medicinal products</p><p>&nbsp;</p><p>Acute lymphatic leukaemia (ALL)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As part of complex therapy protocols in combination with other cytostatic medicinal products for remission-sustaining therapy and for prophylaxis and therapy of leukaemic meningitis</p><p><strong>&nbsp;</strong></p><p><strong>Methotrexat &ldquo;Ebewe&rdquo; in a high dosage (single dose &gt;1000&nbsp;mg/m<sup>2 </sup>BSA) is indicated in the following oncological diseases:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-Hodgkin lymphoma primarily localised in the central nervous system before radiotherapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute lymphatic leukaemia (ALL)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prophylaxis and therapy of leukaemic meningitis</p><p>&nbsp;</p><p>Methotrexat &ldquo;Ebewe&rdquo; tablets, Methotrexat &ldquo;Ebewe&rdquo; 20&nbsp;mg/ml solution for injection in a pre-filled syringe, Methotrexat &ldquo;Ebewe&rdquo; 10&nbsp;mg/ml &ndash; parenteral solution or Methotrexat &ldquo;Ebewe&rdquo; 10&nbsp;mg/ml solution for injection in a pre-filled syringe are suitable for use in severe generalised, refractory psoriasis, psoriatic arthritis and rheumatoid arthritis.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methotrexate should only be prescribed by physicians who are experienced in the use of methotrexate and who are fully aware of the risks of treatment with methotrexate.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>WARNINGS</strong></p><p>The <strong>dose should be carefully adjusted</strong> depending on the body surface area if methotrexate is used for the therapy of <strong>tumours</strong>.</p><p>Cases of fatal intoxication after administration of <strong>incorrectly calculated </strong>doses have been reported. The medical staff and patients must be comprehensively informed of the toxic effects.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Dosage</strong></p><p>The dosage of methotrexate as part of polychemotherapy for malignant tumours or haemoblastoses depends on the indication and takes place individually under consideration of general condition and blood count. The doses applied for conventional, low-dose (single dose below 100&nbsp;mg/m&sup2;), medium-dose (single dose 100&nbsp;mg/m&sup2;&ndash;1000&nbsp;mg/m&sup2;) and high-dose (single dose over 1000&nbsp;mg/m&sup2;) methotrexate therapy are dependent on the respective therapy regimen.</p><p>&nbsp;</p><p>The following dosage information therefore only represents reference values. Current therapy protocols are transmitted to the treating doctor upon request.</p><p>&nbsp;</p><p>Conventional methotrexate therapy &ndash; no calcium folinate protection required</p><p>15&ndash;20&nbsp;mg/m&sup2; (IV); twice a week</p><p>30&ndash;50&nbsp;mg/m&sup2; (IV); once a week</p><p>15&nbsp;mg/m&sup2;/day (IV, IM); 5 days;</p><p>Repeat in 2&ndash;3&nbsp;weeks</p><p>&nbsp;</p><p>Moderately-high dose of methotrexate therapy</p><p>50&ndash;150&nbsp;mg/m&sup2; (IV injection); no calcium folinate protection;</p><p>Repeat in 2&ndash;3&nbsp;weeks</p><p>240&nbsp;mg/m&sup2; (IV infusion over 24&nbsp;h); calcium folinate protection required;</p><p>Repeat in 4&ndash;7 days</p><p>0.5&ndash;1.0&nbsp;g/m&sup2; (IV infusion over 36&ndash;42&nbsp;h); calcium folinate protection required;</p><p>Repeat in 2&ndash;3&nbsp;weeks</p><p>&nbsp;</p><p>High-dose methotrexate therapy &ndash; calcium folinate protection required&nbsp;</p><p>1&ndash;12&nbsp;g/m&sup2; (IV 1&ndash;6&nbsp;h)</p><p>Repeat in 1&ndash;3&nbsp;weeks</p><p>&nbsp;</p><p><strong>a) Systemic (intravenous and intramuscular) administration of methotrexate:</strong></p><p><strong>Low-dose </strong>(single dose below 100&nbsp;mg/m&sup2; BSA) and <strong>medium-dose </strong>(single dose between 100&nbsp;mg/m&sup2; to 1000&nbsp;mg/m&sup2; BSA) <strong>methotrexate therapy</strong>:</p><p>&nbsp;</p><p><strong><em>Malignant trophoblastic tumours (bladder moles, chorionepithelioma):</em></strong></p><p><u>Patients with good prognosis (&ldquo;low risk&rdquo;)</u>: as monotherapy at a dose of 0.4&nbsp;mg/kg body weight (BW) monthly on day&nbsp;1 to 5; repeat after a 7-day break or 0.25&ndash;1&nbsp;mg/kg BW methotrexate monthly on day&nbsp;1, 3, 5 and 7; repeat after a 7-day break; calcium folinate 24&nbsp;h after each methotrexate administration.</p><p><u>Patients with poor prognosis (&ldquo;high risk&rdquo;):</u> 300&nbsp;mg/m&sup2; BSA IV with combination therapy.</p><p>&nbsp;</p><p><strong><em>Breast cancer:</em></strong></p><p>40&nbsp;mg/m&sup2; BSA methotrexate IV on day&nbsp;1 and 8 in combination with cyclophosphamide and fluorouracil analogous to CMF (<strong>c</strong>yclophosphamide, <strong>m</strong>ethotrexate, 5-<strong>f</strong>luorouracil) &ndash; protocol.</p><p>&nbsp;</p><p><strong><em>Tumours in the head and neck area:</em></strong></p><p>40&ndash;60&nbsp;mg/m&sup2; BSA methotrexate IV once weekly as monotherapy.</p><p>&nbsp;</p><p><strong><em>Non-Hodgkin&rsquo;s lymphoma:</em></strong></p><p>Single doses of 120&nbsp;mg/m&sup2; BSA methotrexate as part of combination therapies.</p><p>&nbsp;</p><p><strong><em>Acute lymphatic leukaemia:</em></strong></p><p>For the maintenance of remission as part of complex therapy protocols, single doses of 20 to 40&nbsp;mg/m&sup2; BSA methotrexate.</p><p>&nbsp;</p><p><strong>High-dose methotrexate therapy </strong>(single dose &gt;1000&nbsp;mg/m&sup2; BSA):</p><p>&nbsp;</p><p><strong><em>Non-Hodgkin&rsquo;s lymphoma located mainly in the central nervous system (CNS):</em></strong></p><p>No uniform therapy and dosage schedule can be stated for the therapy of lymphomas primarily localised in the CNS. In trials, doses of at least 1500&nbsp;mg/m&sup2; to 4000&nbsp;mg/m&sup2; BSA methotrexate IV as a single dose over multiple cycles have been shown to be effective as monotherapy or in combination with radiotherapy and/or intrathecally administered methotrexate or with other chemotherapeutically effective medicinal products. Details can be found in the specific professional literature.</p><p>&nbsp;</p><p>For the therapy of non-Hodgkin&rsquo;s lymphoma located mainly in the central nervous system in patients with immunosuppression, e.g., as a result of HIV, please refer to the specific professional literature.</p><p>&nbsp;</p><p><strong><em>Acute lymphatic leukaemia (ALL):</em></strong></p><p>ALL in adults: single doses of 1500&nbsp;mg/m&sup2; BSA methotrexate as part of combination regimens.</p><p>ALL in children and adolescents: typical single doses are in the range of 1000&nbsp;mg/m&sup2; BSA to 5000&nbsp;mg/m&sup2; BSA (as part of combination regimens).</p><p>&nbsp;</p><p><strong>b) Intrathecal administration of methotrexate:</strong></p><p>For prophylaxis and the therapy of leukaemic meningitis and/or the therapy of primary cerebral CNS lymphoma, the intrathecal application of methotrexate has been shown to be effective.</p><p>&nbsp;</p><p>In the case of intrathecal application, methotrexate must be dosed according to age because the CSF volume correlates more closely with the &ndash; age-related &ndash; brain volume than with the body surface or the weight.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children &le;3&nbsp;months 3&nbsp;mg methotrexate intrathecal</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children aged 4 to 11&nbsp;months: 6&nbsp;mg methotrexate via the intrathecal route</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children aged 1&nbsp;year: 8&nbsp;mg methotrexate via the intrathecal route</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children aged 2&nbsp;years: 10&nbsp;mg methotrexate via the intrathecal route</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Children aged 3 to 8&nbsp;years: 12&nbsp;mg methotrexate via the intrathecal route</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients older than 8&nbsp;years: 12&nbsp;mg to maximum 15&nbsp;mg methotrexate via the intrathecal route</p><p>&nbsp;</p><p>The time, frequency and duration of use of the intrathecal methotrexate injections is determined by the treating doctor, taking into account the specific therapy protocols and the individual therapy situation.</p><p>&nbsp;</p><p>Caution: Methotrexate preparations and/or dilutions which contain preservatives may not be used intrathecally or in high doses!</p><p>&nbsp;</p><p><strong>Patients with renal impairment</strong></p><p>Methotrexate is excreted to a significant extent via the kidneys and should therefore be used with caution in patients with renal impairment (see Sections 4.3 and 4.4). The prescribing physician may need to adjust the dose in order to prevent accumulation of the medicinal product. The following dosages are recommended in patients with impaired renal function. Additional dose adjustments may be required due to the large intersubjective pharmacokinetic variability.</p><p>&nbsp;</p><p>Table <!--[if supportFields]><span
lang=EN-GB style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'><span style='mso-element:field-begin'></span><span
style='mso-spacerun:yes'> </span>SEQ Tabelle \* ARABIC <span style='mso-element:
field-separator'></span></span><![endif]-->1<!--[if supportFields]><span
lang=EN-GB style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-ansi-language:
EN-GB'><span style='mso-element:field-end'></span></span><![endif]-->a: Dose adjustment for methotrexate in doses of &lt;100&nbsp;mg/m<sup>2</sup> in patients with renal impairment</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>Creatinine Clearance (ml/min)</p></td><td style="vertical-align:top"><p>% of administered dose</p></td></tr><tr><td style="vertical-align:top"><p>&ge;60</p><p>30&ndash;59</p><p>&lt;30</p></td><td style="vertical-align:top"><p>100</p><p>50</p><p>Methotrexate must not be administered</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Table 1b: Dose adjustment for methotrexate in doses of &gt;100&nbsp;mg/m<sup>2</sup> in patients with renal impairment</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p>Creatinine Clearance (ml/min)</p></td><td style="vertical-align:top"><p>% of administered dose</p></td></tr><tr><td style="vertical-align:top"><p>&gt;80</p><p>~80</p><p>~60</p><p>&lt;60</p></td><td style="vertical-align:top"><p>100</p><p>75</p><p>63</p><p>Methotrexate must not be administered</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Patients with hepatic impairment</strong></p><p>In patients with significant, existing or previous liver disease, especially if this is due to alcohol, methotrexate should be administered with the utmost care, if at all. If bilirubin is &gt;5&nbsp;mg/dl (85.5&nbsp;&mu;mol/l), methotrexate is contraindicated (see Section&nbsp;4.3).</p><p>&nbsp;</p><p><strong>Elderly patients</strong></p><p>Dose reduction should be considered in elderly patients due to the restricted hepatic and renal function and low folic acid reserves with advancing age (55 years and older). In addition, close monitoring of patients for possible signs of toxicity is recommended.<em> </em></p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>The use of methotrexate in children and adolescents must be undertaken with special caution and in line with the corresponding therapy protocols.</p><p>&nbsp;</p><p><strong>Patients with pathological fluid accumulation (pleural effusion, ascites)</strong></p><p>Since the half-life of methotrexate may be prolonged 4-fold in patients with pathologic fluid retention, a reduction in dose, and in many cases, discontinuation of methotrexate can be required (see Sections&nbsp;5.2 and 4.4).</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>For intravenous, intramuscular, intraarterial, intrathecal and intraventricular administration after dilution.</p><p>Methotrexat &ldquo;Ebewe&rdquo; 100&nbsp;mg/ml &ndash; concentrate for the infusion preparation must be diluted before application with standard infusion solutions depending on the therapy regimen and infusion duration. This is possible with a glucose solution or physiological saline solution. In general, 1&ndash;2% Methotrexat &ldquo;Ebewe&rdquo; concentrations are administered.</p><p>&nbsp;</p><p>For these methotrexate solutions, the stability at 25&deg;C (room temperature) for 24&nbsp;hours both under light influence and under light exclusion has been checked. Change infusion bottle for longer infusion times.</p><p>&nbsp;</p><p>Methotrexate preparations and/or dilutions, which contain preservatives <strong>may not</strong> be used intrathecally or in high doses!</p><p>&nbsp;</p><p>Estimation of serum methotrexate levels must be undertaken during treatment with methotrexate.</p><p>&nbsp;</p><p><strong>Calcium folinate</strong></p><p>Calcium folinate (rescue) must be administered after the administration of methotrexate doses of 100&nbsp;mg/m<sup>2</sup> BSA or higher as single dose.</p><p>&nbsp;</p><p>Doses above 100&nbsp;mg/m&sup2; are usually administered as an IV infusion. A portion of it may be injected as an initial dose intravenously (as bolus).</p><p>Methotrexat &ldquo;Ebewe&rdquo; can also be administered intramuscularly, intraarterially, intrathecally and intraventricularly.</p><p>Methotrexat &ldquo;Ebewe&rdquo; 10&nbsp;mg/ml parenteral solution can be used for this or for low-dose regimens.</p><p>&nbsp;</p><p>The total duration of the therapy is determined by the doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance methotrexate or to any of the other excipients listed in Section 6.1 
•	Severe, acute or chronic infections (such as tuberculosis and HIV)
•	Stomatitis, ulcers of the gastrointestinal tract
•	Diseases of the liver due to chronic alcohol abuse or other chronic liver disease (see Section 4.2)
•	Hepatic insufficiency (see Section 4.2)
•	Severe renal impairment (Creatinine Clearance <30 ml/min) for methotrexate in doses of <100 mg/m2 moderate and severe renal impairment (Creatinine Clearance <60 ml/min) for methotrexate in doses of >100 mg/m2 (see Sections 4.2 and 4.4)
•	Dysfunction of the haematopoietic system (e.g., after previous radiotherapy or chemotherapy) such as bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anaemia
•	Immunodeficiency
•	Excessive alcohol consumption
•	Pre-existing blood disease
•	Breastfeeding (see Section 4.6)
•	Pregnancy, unless there is a vital indication (see Section 4.6)
•	Simultaneous vaccination with live vaccines


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The therapy should be carried out by a doctor experienced in tumour therapy and with sufficient experience in the therapy with methotrexate.</p><p>The incorrect use of methotrexate can lead to severe, including fatal, side effects. Healthcare professionals and patients must be clearly instructed.</p><p>&nbsp;</p><p><u>Toxicity</u></p><p>During therapy with methotrexate, patients must be closely monitored due to the possibility of severe toxic reactions (which can prove fatal) so that any symptoms of poisoning can be detected quickly.</p><p>Patients should be educated on the potential benefits and risks (including the early signs and symptoms of toxicity) of methotrexate therapy. In addition, they should be informed of the need to consult a doctor as soon as they detect the occurrence of symptoms of poisoning, as well as about the necessary monitoring of symptoms of poisoning (including regular laboratory tests).</p><p>&nbsp;</p><p>The discontinuation of methotrexate does not always result in the full regression of the side effects that occurred.</p><p>&nbsp;</p><p>Estimation of serum methotrexate levels must be undertaken during treatment with methotrexate.</p><p>&nbsp;</p><p>Methotrexate is only slowly eliminated from the <strong>pathological fluid collections </strong>such as ascites or pleural effusions<strong> in body cavities</strong> (the so-called &ldquo;third space&rdquo;), which results in an extended plasma elimination half-life and unexpected toxicity. These fluid collections must be removed by puncture, if possible, before therapy with methotrexate.</p><p>&nbsp;</p><p><u>Blood and lymphatic system</u></p><p>Methotrexate can suppress the <strong>haematopoietic system</strong>, thereby causing anaemia, aplastic anaemia, pancytopenia, leukopenia, neutropenia and/or thrombocytopenia.</p><p>First signs of these life-threatening complications can include: fever, sore throat, ulceration of the mucous membrane of the mouth, flu-like complaints, severe exhaustion, nose bleeds and skin bleeding.</p><p>In the therapy of neoplastic conditions, the methotrexate therapy should be continued only if the potential benefit outweighs the risk of severe myelosuppression.</p><p>&nbsp;</p><p>Especially during long-term therapy in elderly patients, there were reports of <strong>megaloblastic anaemia</strong>.</p><p>&nbsp;</p><p>Methotrexate should not be administered if peptic ulcer or ulcerative colitis is present (see Section&nbsp;4.3).</p><p>&nbsp;</p><p>Special attention must be paid to the <strong>patient&rsquo;s condition following therapy with medicinal products with cumulative myelotoxicity </strong>and <strong>radiation therapy involving the bone marrow, </strong>in particular for any restrictions to the bone marrow reserve. This can result in the increased sensitivity of the bone marrow to the methotrexate therapy and the increased suppression of the haematopoietic system. For longer-lasting therapy with methotrexate, bone marrow biopsies should be carried out as necessary.</p><p>&nbsp;</p><p>In the case of <strong>acute lymphatic leukaemia, </strong>methotrexate may induce pain in the left epigastric region (inflammation of the splenic capsule due to the destruction of leukaemic cells).</p><p>&nbsp;</p><p><u>Liver function</u></p><p>Due to the potentially <strong>hepatotoxic effects</strong> it is recommended that no additional hepatotoxic or potentially hepatotoxic medicinal products are taken during methotrexate therapy and to abstain from alcohol consumption or to significantly reduce alcohol consumption.</p><p>&nbsp;</p><p>Methotrexate can cause acute <strong>hepatitis </strong>and chronic, potentially fatal <strong>hepatotoxicity </strong>(fibrosis and cirrhosis), but&nbsp;generally only after prolonged use. Acutely elevated levels of liver-related enzymes are commonly observed. These are&nbsp;generally transient and asymptomatic and do not indicate the probability of subsequent liver disease.</p><p>&nbsp;</p><p>Methotrexate caused the <strong>reactivation of a hepatitis B infection or the worsening of hepatitis&nbsp;C infections</strong>, which in some cases resulted in death. Some cases of hepatitis B reactivation occurred after the discontinuation of methotrexate. To be able to assess a pre-existing liver disease in patients with previous hepatitis B or C infections, clinical and laboratory tests should be performed. Based on the results of this, a methotrexate therapy can then be shown to be inappropriate for some patients.</p><p>&nbsp;</p><p>Also, where there are other <strong>inactive, chronic infections </strong>e.g., herpes zoster or tuberculosis, special care is advised due to the possibility of activation.</p><p>&nbsp;</p><p>In the case of patients with <strong>insulin-dependent diabetes mellitus</strong>, increased caution is advised as a rule, since under a methotrexate therapy, liver cirrhosis without intermittently elevated transaminases has developed in individual cases.</p><p>&nbsp;</p><p><u>Renal function</u></p><p>In patients with <strong>impaired renal function, </strong>the methotrexate therapy should only be performed with extreme caution and with a low dosage due to the delayed methotrexate elimination levels in these patients (see Section 4.2).</p><p>&nbsp;</p><p>Under therapy with methotrexate, a worsening of the kidney function with an increase in specific laboratory values (creatinine, urea and uric acid in serum) can develop, resulting in <strong>acute renal failure </strong>with oliguria or anuria. This is probably caused by the precipitation of methotrexate and its metabolites in the renal tubules.</p><p>&nbsp;</p><p>Conditions that lead to <strong>dehydration</strong>, such as vomiting, diarrhoea and stomatitis, can increase the toxicity of methotrexate due to the increased levels of the active substance. In these cases, a supporting therapy should be initiated and the suspension of the use of methotrexate should be considered until the symptoms abate.</p><p>&nbsp;</p><p><u>Gastrointestinal Disorders</u></p><p>If <strong>ulcerative stomatitis </strong>or <strong>diarrhoea</strong>, <strong>haematemesis</strong>, <strong>black colouration of the stool </strong>or <strong>blood in the stool </strong>should occur, the therapy must be interrupted, because otherwise haemorrhagic enteritis and cases of death by intestinal perforation can occur.</p><p>&nbsp;</p><p><u>Nervous system</u></p><p>Cases of <strong>leukoencephalopathy </strong>were reported after intravenous administration of methotrexate in patients who had<strong> previously received cranial irradiation</strong>.</p><p>Chronic leukoencephalopathy has also been reported in patients who were given repeated high-dose therapy with methotrexate with calcium folinate rescue without prior cranial irradiation.</p><p>There is some evidence that the combined use of cranial irradiation together with the intrathecal application of methotrexate increases the incidence of leukoencephalopathy (also see Section&nbsp;4.8).</p><p>There are reports about the occurrence of leukoencephalopathy in patients who were given <em>oral </em>methotrexate.</p><p>&nbsp;</p><p>After the <strong>intrathecal application </strong>of methotrexate, patients must be monitored for the development of signs of neurotoxicity (damage to the nervous system, such as meningeal irritation, temporary or sustained paralysis, encephalopathy).</p><p>&nbsp;</p><p>Cases of serious neurological effects, which ranged from headache to paralysis, coma and stroke-like episodes, were predominantly observed in children and adolescents who had been given methotrexate <strong>intrathecal </strong>in <strong>combination with cytarabine IV</strong>.</p><p>&nbsp;</p><p>A transient <strong>acute neurological syndrome</strong> has also been seen with high-dose methotrexate therapy, which may manifest as behavioural abnormalities, focal sensorimotor symptoms (including transient blindness) and abnormal reflexes. The exact cause is unknown.</p><p>&nbsp;</p><p><u>Lung function</u></p><p>Special care is recommended for patients with <strong>impaired lung function</strong>.</p><p>&nbsp;</p><p><strong>Pulmonary complications, pleural effusion, alveolitis or pneumonitis </strong>with symptoms such as irritative cough, fever,&nbsp;general malaise, cough, chest pain, dyspnoea, hypoxemia and infiltrates in the chest X-ray or non-specific pneumonia occurring during the methotrexate therapy, can be signs of possible hazardous damage, which can potentially prove to be fatal. Lung biopsies revealed different findings (e.g., interstitial oedema, mononuclear infiltrates or non-caseating granulomas). If these complications should be suspected, the therapy with methotrexate must be discontinued immediately and a thorough investigation, including tests to exclude any possibility of infections and tumours, is required. Methotrexate induced lung disorders can occur acutely at any time during the therapy, were not always completely reversible, and were reported even at low doses of 7.5&nbsp;mg/week.</p><p>&nbsp;</p><p>In addition, pulmonary alveolar bleeding has been reported with the use of methotrexate in rheumatologic and similar indications. This event may also be associated with vasculitis and other comorbidities. If there is a suspicion of pulmonary alveolar bleeding, an immediate examination should be considered to confirm the diagnosis.</p><p>&nbsp;</p><p><u>Skin and subcutaneous tissue disorders</u></p><p>There are reports of the occurrence of severe, sometimes fatal, <strong>skin reactions </strong>such as Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell&rsquo;s syndrome) after a single dose of methotrexate or continuous administration.</p><p>&nbsp;</p><p>Psoriatic lesions can be aggravated by <strong>UV radiation </strong>with simultaneous methotrexate therapy. Radiation-induced dermatitis and sunburn can recur with the use of methotrexate (&ldquo;recall&rdquo; reactions).</p><p>&nbsp;</p><p><u>Immune system</u></p><p>During methotrexate therapy, <strong>opportunistic infections, </strong>including pneumocystis jirovecii pneumonia may occur, which can prove to be fatal. If a patient presents with pulmonary symptoms, the possibility of pneumocystis jirovecii pneumonia should be considered.</p><p>&nbsp;</p><p>Due to its potential effect on the immune system methotrexate can distort<strong> vaccination and test results </strong>(immunological test procedures to record immunoreactivity). During therapy with methotrexate, vaccinations that are&nbsp;given can prove to be ineffective. <strong>Live vaccines</strong> should not be administered during therapy with methotrexate due to the increased risk of infection.</p><p>&nbsp;</p><p>Methotrexate should be used with caution in patients with active infections. Methotrexate is contraindicated in patients with obvious or laboratory-confirmed immunodeficiency syndromes. Also, caution should be exercised when administering methotrexate if patients are exposed to chickenpox or shingles.</p><p>&nbsp;</p><p><u>Neoplasms</u></p><p>In patients with fast growing tumours, methotrexate, as well as other cytostatic medicinal products, can induce <strong>tumour lysis syndrome</strong>. Appropriate supportive and pharmacologic actions can prevent or mediate these complications.</p><p>&nbsp;</p><p>Occasionally, the <strong>occurrence of malignant lymphoma </strong>was reported with the use of low-dosage methotrexate, which receded in some cases after the discontinuation of therapy with methotrexate. In the case of the incidence of lymphomas, the methotrexate therapy should thus be discontinued, and a suitable therapy introduced only if the lymphoma does not regress. An increased incidence of the occurrence of lymphoma under therapy with methotrexate could not be determined in a recent investigation.</p><p>&nbsp;</p><p>The use of high-dose regimens for the therapy of neoplastic conditions outside of the approved indications is of an investigative nature only; a therapeutic benefit for this has not been established.</p><p>&nbsp;</p><p><u>Musculoskeletal, connective tissue and bone disorders</u></p><p>The risk of the occurrence of soft tissue necrosis, or osteonecrosis, can be increased with <strong>radiotherapy </strong>during the use of methotrexate.</p><p>&nbsp;</p><p><u>Folic acid supplement</u></p><p><strong>Insufficient folic acid </strong>can increase the toxicity of methotrexate (see Section&nbsp;4.5).</p><p>The use of folic or folinic acid can reduce the toxicity of methotrexate (gastrointestinal symptoms, stomatitis, alopecia and increase in liver enzymes).</p><p>Before taking folic acid supplements, the monitoring of vitamin B12 levels is recommended, since the administration of folic acid can mask a vitamin B12 insufficiency, in particular in adults aged over 50.</p><p>&nbsp;</p><p><strong><u>Recommended follow-up examinations and safeguards</u></strong></p><p>&nbsp;</p><p>Patients undergoing methotrexate therapy should be closely monitored in order to detect toxic effects immediately.</p><p>&nbsp;</p><p><u>Before the start of therapy,</u> the following examinations should be performed:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complete blood count with differential blood count</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatic enzymes (ALAT [GPT], ASAT [GOT], AP), bilirubin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serum albumin</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Renal retention parameters (if applicable, with creatinine clearance)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hepatitis serology (A, B, C)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Exclusion of tuberculosis, if applicable</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chest X-rays, if applicable</p><p>If a pulmonary disease (e.g., interstitial pneumonia) is suspected, lung function tests, particularly in the presence of corresponding reference values from the initial examination may be beneficial.</p><p>&nbsp;</p><p>Depending on the dosage and/or the therapeutic protocol used, regular <strong>monitoring of methotrexate serum levels </strong>is required, especially during and after therapy with methotrexate in high doses (also see Section&nbsp;4.9). By adjusting the methotrexate dose and implementing appropriate rescue measures, the toxicity and possible mortality of a methotrexate therapy can be significantly decreased.</p><p>Patients who suffer from pleural effusions, ascites, gastrointestinal tract occlusion, previous cisplatin therapy, dehydration, reduced urinary pH or impaired or damaged kidneys are particularly susceptible to developing elevated or only delayed decreasing methotrexate levels and must be strictly monitored.</p><p>Even without the aforementioned apparent reasons, some patients may also have delayed methotrexate elimination. It is important to identify these patients within 48&nbsp;hours after the therapy, otherwise the methotrexate toxicity can be irreversible.</p><p>&nbsp;</p><p>A <strong>calcium folinate protective (rescue) therapy </strong>must be carried out following therapy with methotrexate with a dosage of 100&nbsp;mg/m<sup>2 </sup>BSA. Depending on the quantity of methotrexate and the infusion time, different calcium folinate doses are necessary to protect the normal regenerative tissue from severe toxic side effects.</p><p>An adequate calcium folinate rescue must be initiated within 42 to 48&nbsp;hours after methotrexate therapy. Follow-up checks of the methotrexate levels should therefore be carried out after at least 24, 48 and 72&nbsp;hours and continued, if necessary, to determine how long the calcium folinate rescue must be continued.</p><p>&nbsp;</p><p>During therapy with methotrexate, <strong>complete blood count monitoring </strong>should be performed with differential blood counts, including platelet and leukocyte counts (daily to once weekly).</p><p>The leukocyte and platelet counts should be assessed before the initiation of a combination therapy with methotrexate in a high dosage with regard to the specified minimum values in the respective protocol (leukocytes 1000 to 1500/&mu;l, thrombocytes 50,000 to 100,000/&mu;l).</p><p>&nbsp;</p><p>The lowest value of circulating leukocytes, neutrophil granulocytes and thrombocytes generally occurs 5&ndash;13&nbsp;days after IV use of methotrexate (with rebound after 14&ndash;28&nbsp;days). Leukocytes and neutrophil granulocytes occasionally show two decreases, whereby the first occurs after 4&ndash;7&nbsp;days and the second after 12&ndash;21&nbsp;days, followed by a rebound.</p><p>&nbsp;</p><p><strong>Liver and kidney function tests </strong>and <strong>urine tests </strong>should be performed at regular intervals.</p><p>&nbsp;</p><p>Temporary 2 to 3-fold <strong>increases in transaminases </strong>were observed in 13&ndash;20% of patients receiving methotrexate therapy. This is not&nbsp;generally a reason for changing the dosing regimen. However, sustained anomalies in the liver-related enzymes and/or a decrease in the serum albumin can be a sign of serious hepatotoxicity. In the case of a <strong>sustained increase</strong> in the liver-related enzymes, a reduction and/or the suspension of the therapy must be considered. In patients with a <strong>longer history of hepatic impairment, </strong>methotrexate should always be discontinued.</p><p>Enzyme determination does not allow a reliable prediction of the development of morphologically tangible liver injury, i.e., even with normal transaminases there may only be a histologically detectable liver fibrosis or, more rarely, liver cirrhosis.</p><p>&nbsp;</p><p>The use of methotrexate may result in a worsening of <u>kidney function</u>.</p><p><strong>Monitoring</strong> <strong>of creatinine, urea and electrolytes, </strong>especially in therapy with methotrexate in high doses, is recommended on&nbsp;days&nbsp;2 and 3 to detect an excretion disorder caused by methotrexate early on.</p><p>Therapy with methotrexate may result in <u>acute renal failure</u> with oliguria/anuria and a rise in the serum creatinine, probably due to the precipitation of methotrexate and its metabolites in the renal tubules. Monitoring of renal function, including adequate hydration and alkalinisation of urine, measurement of serum methotrexate levels and monitoring of urine output is recommended.</p><p>&nbsp;</p><p>If there are any indications of an <strong>impairment of renal function </strong>(e.g., pronounced side effects of prior methotrexate therapy or urinary obstruction), the creatinine clearance must be determined. Therapy with high-dose methotrexate (methotrexate doses &gt;100&nbsp;mg/m<sup>2</sup>) should only be undertaken if creatinine is normal (creatinine clearance &gt;80&nbsp;ml/min) (see Sections 4.2 and 4.3). Since methotrexate is primarily eliminated by the kidneys, higher concentrations are to be expected in patients with impaired kidney function, which may lead to serious side effects.</p><p>The dosage should be reduced in case serum creatinine levels are elevated. Methotrexate should not be administered if creatinine clearance is less than 30&nbsp;ml/min. Treatment with methotrexate in doses above 100&nbsp;mg/m<sup>2</sup> is contraindicated if serum creatinine is higher than 2&nbsp;mg/dl and creatinine clearance is less than 60&nbsp;ml/min (see Sections 4.2 and 4.3). Treatment with methotrexate over 100&nbsp;mg/m<sup>2</sup> should not be initiated with a urinary pH less than 7.0. Alkalinisation of the urine must be tested at least for the first 24&nbsp;hours by repeated pH monitoring (values greater than or equal to 6.8) after beginning treatment with methotrexate. Administration of adequate amounts of intravenous fluid is absolutely necessary during therapy with high-dose methotrexate.</p><p>Monitoring should be undertaken at shorter intervals in case there is a possibility of renal dysfunction or borderline renal function (e.g., elderly patients). This applies, in particular, if additional medicinal products are administered that impede the clearance of methotrexate, cause kidney damage (e.g., non-steroidal anti-inflammatory medicinal products) or can lead to haematopoietic disorders. Concomitant administration of NSAIDs is not recommended in the presence of risk factors such as renal dysfunction, including mild renal impairment. The concomitant use of proton pump inhibitors and high-dose methotrexate should be avoided, especially in patients with impaired renal function.</p><p>&nbsp;</p><p>Conditions which lead to <strong>dehydration</strong>, such as vomiting, diarrhoea and stomatitis, may increase the toxicity of methotrexate due to higher levels of the active substance. In these cases, the use of methotrexate should be discontinued until the symptoms abate.</p><p>&nbsp;</p><p>An <strong>inspection of the oral cavity and pharynx </strong>for mucosal changes should be done daily.</p><p>&nbsp;</p><p>Particularly <strong>strict patient monitoring </strong>is necessary in the case of previous intensive radiotherapy, reduced general state of health of the patient and in young or elderly patients.</p><p>&nbsp;</p><p><strong>More frequent follow-up examinations </strong>may be required at the start of therapy, in the case of dosage changes, or during a phase in which there is an increased risk of elevated methotrexate levels (e.g., dehydration, impaired renal function, additional or increased co-administered medicinal products such as non-steroidal anti-inflammatory medicinal products).</p><p>&nbsp;</p><p><u>Use in children and adolescents</u></p><p>Special caution is indicated for the use of methotrexate in the therapy of children and adolescents. The therapy should follow the therapy protocols especially developed for children.</p><p>In <strong>paediatric patients with acute lymphatic leukaemia (ALL)</strong>, severe <strong>neurotoxicity</strong><sup> </sup>may occur following therapy with medium-dose intravenous methotrexate (1&nbsp;g/m<sup>2</sup><strong> </strong>BSA), which is commonly reported as a generalised or focal epileptic seizure. Leukoencephalopathy and/or microangiopathic calcifications were often observed in diagnostic imaging for symptomatic patients.</p><p>&nbsp;</p><p><u>Use in elderly patients</u></p><p>Special caution is also advised in elderly patients. Elderly patients should be examined at short time intervals to detect early signs of toxicity. The clinical pharmacology of methotrexate has not been fully investigated in the elderly. The dose of methotrexate should be adjusted to the decreased liver and renal function due to increased age. For older patients (55&nbsp;years and older), partially modified therapy protocols, such as for ALL therapy, have been developed.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>Methotrexate has been reported to cause fertility disorders, oligospermia, menstrual disorders and amenorrhoea during treatment and for a short period after termination of therapy in humans by interfering with spermatogenesis and oogenesis during the period of administration &ndash; these effects appear to be reversible when treatment is discontinued.</p><p>&nbsp;</p><p><u>Teratogenicity &ndash; risk for reproduction</u></p><p>Methotrexate causes embryotoxicity, abortion and foetal birth defects in humans. Therefore, potential reproductive, miscarriages and congenital birth defects should be discussed with patients of childbearing potential (see Section&nbsp;4.6). If women of childbearing potential are treated, an effective method of contraception should be used during therapy and for a period of at least six&nbsp;months after discontinuation of therapy.</p><p>&nbsp;</p><p><u>Use in men</u></p><p>Methotrexate can have a <strong>genotoxic effect</strong>. Therefore, men treated with methotrexate are advised not to father a child during therapy and up to 6&nbsp;months thereafter. Since therapy with methotrexate can cause severe and possibly irreversible spermatogenesis disorders, men should seek advice on the possibility of <strong>sperm preservation </strong>prior to initiation of therapy (for advice on male contraception, see Section&nbsp;4.6).</p><p>&nbsp;</p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per vial, i.e., it is essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of <strong>nitrous oxide (laughing gas) </strong>potentiates the effect of methotrexate on folate metabolism and leads to increased toxicity such as severe, unpredictable myelosuppression, stomatitis and neurotoxicity following <strong>intrathecal administration</strong>. The concomitant use of methotrexate and nitrous oxide should therefore be avoided, although this effect may be alleviated by the administration of calcium folinate.</p><p>&nbsp;</p><p><strong>L-asparaginase </strong>antagonises the effects of methotrexate in concomitant use with methotrexate.</p><p>&nbsp;</p><p><strong>Disease-modifying antirheumatic drugs (DMARDs) and non-steroidal anti-inflammatory drugs (NSAIDs) </strong>should not be administered before or during a <u>high-dose methotrexate therapy</u>. The concomitant use of NSAIDs and high-dose methotrexate resulted in increased and prolonged methotrexate serum levels, resulting in cases of death due to severe haematological (myelosuppression and aplastic anaemia) and gastrointestinal toxicity.</p><p>In animal tests, non-steroidal anti-inflammatory medicinal products (NSAIDs), including salicylic acid, led to a reduction in the tubular secretion of methotrexate and thus to an increase in its toxicity due to the elevated methotrexate level. Therefore, <u>NSAIDs and low-dose methotrexate </u>should only be used concomitantly with caution. In the presence of risk factors, such as impaired kidney function &ndash; even if borderline &ndash; the concomitant use with non-steroidal antiphlogistics is discouraged.</p><p>&nbsp;</p><p>The concomitant use of methotrexate and <strong>DMARDs </strong>(e.g., gold compounds, penicillamine, hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine) has not been studied and thus the intensification of the toxic effects of methotrexate cannot be excluded.</p><p>&nbsp;</p><p>The co-administration of <strong>proton pump inhibitors </strong>(omeprazole, pantoprazole, lansoprazole) may cause a delay in or inhibition of the renal elimination of methotrexate and therefore cause increased methotrexate plasma levels with clinical signs and symptoms of methotrexate toxicity.</p><p>The concomitant use of proton pump inhibitors with high-dose methotrexate should therefore be avoided, especially in patients with impaired renal function.</p><p>&nbsp;</p><p>The <strong>hepatotoxicity </strong>can be increased by regular alcohol consumption or the use of other hepatotoxic medicinal products such as <strong>azathioprine, leflunomide, retinoids</strong> <strong>and sulfasalazine</strong>. Patients who also take hepatotoxic medicinal products should be monitored closely. Alcohol consumption should be avoided during therapy with methotrexate.</p><p><strong>&nbsp;</strong></p><p>Through the <strong>displacement of methotrexate from the plasma protein binding</strong>, the following medicinal products can increase the biological availability of methotrexate (indirect dosage escalation) and increase its toxicity: aminopyridine derivatives, para-amino benzoic acid, barbiturates, doxorubicin, oral contraceptives, phenylbutazone, phenytoin, probenecid, salicylates, sulphonamides, tetracyclines, tranquilizers, sulfonylureas, penicillin, pristinamycin and chloramphenicol. The concomitant use of methotrexate should therefore be monitored carefully.</p><p>&nbsp;</p><p>A <strong>reduction in tubular secretion </strong>and consequently an increase in the toxicity of methotrexate, especially in the low dosage range, may be caused by the following medications: para-aminohippuric acid, non-steroidal anti-inflammatory medicinal products, probenecid, salicylates, sulphonamides and other weak organic acids. The concomitant use of methotrexate should therefore be monitored carefully.</p><p>&nbsp;</p><p><strong>Penicillin </strong>and <strong>sulphonamides </strong>can reduce the renal clearance of methotrexate in individual cases, so that increased concentrations of methotrexate with concomitant haematologic and gastrointestinal toxicity may occur.</p><p>&nbsp;</p><p>The tubular secretion in the kidneys is decreased by <strong>ciprofloxacin</strong>; the use of methotrexate with this medicinal product should be monitored carefully.</p><p>&nbsp;</p><p><strong>Oral antibiotics </strong>such as tetracyclines, chloramphenicol and non-resorbable broad-spectrum antibiotics can reduce the intestinal absorption of methotrexate or influence enterohepatic circulation by inhibiting the gut flora and metabolism of methotrexate by bacteria.</p><p>&nbsp;</p><p>In the case of <strong>(prior) therapy with medicinal products that can have possible</strong> <strong>side effects for the bone marrow</strong> (e.g., amidopyrine derivatives, chloramphenicol, phenytoin, pyrimethamine, sulphonamides, trimethoprim/sulfamethoxazole, cytostatics), the possibility of pronounced disorders of the haematopoiesis through the therapy with methotrexate must be taken into consideration.</p><p>&nbsp;</p><p>The co-administration of <strong>medicinal products that cause a folate deficiency </strong>(e.g., sulphonamides, trimethoprim/sulfamethoxazole) can lead to increased methotrexate toxicity. Special caution is therefore also advised in the case of an existing folic acid deficiency. On the other hand, the concomitant use of <strong>medicinal products containing folic acid </strong>and <strong>vitamin preparations</strong> <strong>that contain folic acid</strong> <strong>or their derivatives</strong> can inhibit the efficacy of methotrexate.</p><p><strong>&nbsp;</strong></p><p>Although the combination of methotrexate and <strong>sulfasalazine </strong>can cause a potentiation of methotrexate and thus more severe side effects due to the inhibition of the folic acid synthesis by sulfasalazine, in several studies such side effects were observed in patients only in rare individual cases.</p><p>&nbsp;</p><p>Methotrexate can reduce <strong>theophylline</strong> clearance. Therefore, in the case of co-administration with methotrexate, the theophylline levels must be monitored.</p><p>&nbsp;</p><p>Excessive consumption of <strong>beverages containing caffeine or theophylline </strong>(coffee, caffeinated drinks, black tea) should be avoided during therapy with methotrexate, as the effect of methotrexate may be reduced due to the potential interaction between methotrexate and methylxanthines on the adenosine receptors.</p><p>&nbsp;</p><p>The combined use of methotrexate with <strong>leflunomide </strong>can increase the risk of pancytopenia.</p><p>&nbsp;</p><p>Concomitant use of <strong>mercaptopurine </strong>and methotrexate can increase the plasma level of mercaptopurine, so that dose adjustment may be required when administered concomitantly.</p><p><strong>&nbsp;</strong></p><p>Cases of bone marrow suppression and reduced blood folate levels have been described in connection with the concomitant use of <strong>triamterene </strong>and methotrexate.</p><p>&nbsp;</p><p>The risk of the occurrence of soft tissue necrosis or osteonecrosis can be increased with <strong>radiotherapy </strong>during the use of methotrexate.</p><p>&nbsp;</p><p><strong>Cholestyramine </strong>can increase the non-renal elimination of methotrexate through an interruption of the enterohepatic cycle.</p><p>&nbsp;</p><p>In the case of co-administration of <strong>erythrocyte concentrates </strong>and methotrexate, special monitoring of the patient is required. Patients who subsequently receive blood transfusions after methotrexate infusions over 24&nbsp;hours may experience increased toxicity due to prolonged serum methotrexate concentrations that are persistently high.</p><p>&nbsp;</p><p>In individual cases,<strong> </strong><strong>corticosteroids </strong>led to disseminated herpes zoster in patients with herpes zoster or postherpetic neuralgia when administered concomitantly with methotrexate.</p><p>&nbsp;</p><p><strong>High-dosage calcium folinate </strong>can reduce the efficacy of methotrexate administered via the intrathecal route.</p><p>&nbsp;</p><p><strong>Anaesthetics</strong> <strong>on a nitrous oxide base</strong> potentiate the effect of methotrexate on the folic acid metabolism and cause increased toxicity such as severe, not foreseeable myelosuppression, stomatitis and neurotoxicity in the case of application via the intrathecal route. This can be reduced by the administration of calcium folinate.</p><p><strong>&nbsp;</strong></p><p><strong>Pyrimethamine </strong>or <strong>cotrimoxazole </strong>used in combination with methotrexate can cause pancytopenia, probably due to the additive inhibition of dihydrofolic acid caused by these substances and methotrexate (interactions between sulphonamides and methotrexate see above).</p><p>&nbsp;</p><p>Regular <strong>consumption of alcohol </strong>and administration of additional hepatotoxic medicinal products increase the likelihood of hepatotoxic side effects of methotrexate.</p><p>&nbsp;</p><p>The administration of additional haematotoxic medicinal products (e.g., metamizole) increases the likelihood of severe haematotoxic side effects of methotrexate.</p><p>&nbsp;</p><p>The pharmacokinetic interactions between methotrexate, anticonvulsants (reduced serum methotrexate levels) and 5-fluorouracil (increased half-life of 5-fluorouracil) must be considered.</p><p>&nbsp;</p><p>Especially in the case of orthopaedic interventions, where the risk of infection is high, combination therapy of methotrexate with immunomodulatory medicinal products should be used with caution.</p><p>&nbsp;</p><p>Delayed clearance of methotrexate should be considered in combination with other cytostatic active substances.</p><p>&nbsp;</p><p>A reduction in the <strong>phenytoin</strong> plasma level was observed in patients with acute lymphatic leukaemia during induction therapy that included high-dose methotrexate with calcium folinate rescue as well as prednisone, vincristine, and 6-mercaptopurine.</p><p>&nbsp;</p><p>The use of <strong>procarbazine </strong>during a high-dose methotrexate therapy increases the risk of renal function impairment.</p><p>&nbsp;</p><p>In the case of simultaneous intrathecal application of methotrexate with <strong>cytarabine IV</strong>, the risk of serious neurological side effects, such as headache, paralysis, coma and stroke-like episodes may be increased.</p><p>&nbsp;</p><p>An <strong>increase in nephrotoxicity </strong>may occur in combination with high-dose methotrexate with a potentially nephrotoxic chemotherapy agent (e.g., cisplatin).</p><p>&nbsp;</p><p>Considering its possible effects on the immune system, methotrexate may distort vaccination and test results (immunological processes to assess the immune response).</p><p>&nbsp;</p><p>During methotrexate therapy, concomitant <strong>vaccination with live vaccines </strong>must not be carried out (see Sections 4.3 and 4.4).</p><p><strong>&nbsp;</strong></p><p>Methotrexate may increase the effect of coumarin-like oral anticoagulants (acenocoumarol, phenprocoumon) (prolonged prothrombin time due to reduced degradation of coumarin derivatives).</p><p>&nbsp;</p><p>Co-administration of levetiracetam and methotrexate reduces the methotrexate clearance and results in increased/prolonged methotrexate levels in the blood up to potentially toxic levels. Methotrexate and levetiracetam blood levels should be monitored carefully in patients receiving both medicinal products at the same time.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in women</u></p><p>Women must not become pregnant during methotrexate therapy. Reliable contraception is to be used during therapy and for a period of at least 6&nbsp;months after discontinuation of therapy with methotrexate (see Section&nbsp;4.4). Women of childbearing potential should be informed of the risk of birth defects associated with methotrexate prior to the initiation of therapy and the possibility of pregnancy should be reliably excluded by taking appropriate measures, such as a pregnancy test. During therapy, pregnancy tests should be repeated in accordance with clinical needs (e.g., after interruption of contraception). Patients of childbearing potential should be counselled about pregnancy prevention and planning. Couples should be fully informed of the serious risks to the foetus in the case of pregnancy during the therapy.</p><p>&nbsp;</p><p><u>Contraception in men</u></p><p>It is not known if methotrexate accumulates in semen. In animal studies, methotrexate has been found to be&nbsp;genotoxic so that the risk of&nbsp;genotoxic effects on the sperm cannot be completely ruled out. Limited clinical evidence does not indicate that there is an increased risk of birth defects or miscarriages if the father received methotrexate in low doses (less than 30&nbsp;mg/week). For higher doses, there is insufficient data to estimate the risk of birth defects or miscarriages after paternal exposure.</p><p>As a precautionary measure, sexually active male patients or their partners are recommended to use reliable contraception during therapy of the male patient and for at least 6&nbsp;months after stopping methotrexate. Men should not donate semen during therapy and for a period of 6&nbsp;months after discontinuation of methotrexate.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Methotrexate is contraindicated in non-oncological indications during pregnancy (see Section&nbsp;4.3). If pregnancy occurs during therapy with methotrexate and within up to six months after discontinuation of methotrexate, medical advice should be provided on the risk of harmful therapy-related effects to the child and ultrasound scans should be performed to confirm the normal development of the foetus.</p><p>In animal studies, methotrexate has been shown to cause reproductive toxicity, especially in the first trimester (see Section&nbsp;5.3). It has been shown that methotrexate has a teratogenic effect in humans; it has been reported to cause death of the foetus, miscarriages and/or congenital anomalies (e.g., craniofacial, cardiovascular, central nervous system and extremity abnormalities).</p><p>Methotrexate is a potent teratogen for humans, increasing the risk of spontaneous abortion, intrauterine growth disorders and congenital birth defects in case of exposure during pregnancy.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spontaneous abortions were observed in 42.5% of pregnant women receiving methotrexate therapy at low doses (less than 30&nbsp;mg/week). In patients with a similar disease treated with medicinal products other than methotrexate, the reported miscarriage rate was 22.5%.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious birth defects occurred in 6.6% of live births in women who received methotrexate at low doses (less than 30&nbsp;mg/week) during pregnancy. Approximately 4% of live births were affected in patients with a similar disease treated with medicinal products other than methotrexate.</p><p>&nbsp;</p><p>There is insufficient data on exposure to doses of methotrexate higher than 30&nbsp;mg/week during pregnancy, but higher rates of spontaneous abortion and congenital birth defects are to be expected.</p><p>Normal pregnancies were reported when methotrexate was discontinued before conception.</p><p>&nbsp;</p><p>If used in oncological indications, methotrexate should not be administered during pregnancy and particularly not in the first trimester of pregnancy. The benefit of therapy must be weighed against the potential risk to the foetus in each case. If the medicinal product is used during pregnancy, or if the patient becomes pregnant during therapy with methotrexate, she should be informed about the potential risk to the foetus.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Since methotrexate enters the mother&rsquo;s milk and can cause toxic effects in nursing children, the therapy is contraindicated during breastfeeding (see Section&nbsp;4.3). If the therapy is necessary during breastfeeding, breastfeeding must be discontinued before the therapy starts.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Methotrexate affects spermatogenesis and oogenesis and may reduce fertility. It has been reported that methotrexate causes oligospermia, menstrual disorders and amenorrhoea in humans. These effects appear to be reversible in most cases after discontinuation of therapy.</p><p>In oncological indications, women intending to become pregnant are advised to consult a genetic counselling office, if possible, before starting therapy, and men should seek advice regarding the possibility of sperm preservation before starting therapy since methotrexate may be genotoxic in higher doses (see Section&nbsp;4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methotrexate has a low or moderate effect on the ability to drive and to operate machinery. Since central nervous system impairments such as fatigue and dizziness may occur during therapy. In some cases the ability to drive and/or operate machinery may be compromised. This is especially true in connection with alcohol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The incidence and severity of side effects usually depends on the dosage and duration of the methotrexate therapy. Because serious side effects can occur even at lower doses at any time during the therapy, regular monitoring by the doctor at short time intervals is essential. Most side effects are reversible if they are detected early. Some of the severe side effects mentioned below can, however, result in sudden death in very rare cases.</p><p>&nbsp;</p><p>If side effects should occur, depending on their severity and intensity, dosage should be reduced, or the therapy interrupted, and appropriate countermeasures initiated (see Section&nbsp;4.9). If the therapy with methotrexate is to be resumed, this should be initiated with caution under a careful evaluation of the necessity of the therapy and with increased vigilance with regard to the possible recurrence of toxicity.</p><p>&nbsp;</p><p>Myelosuppression and mucositis are generally the dosage-limiting toxic effects that occur. The severity of these effects depends on the dosage, the type and the duration of use of methotrexate. Mucositis occurred approx. 3&ndash;7&nbsp;days after the administration of methotrexate, leukopenia and thrombocytopenia 5&ndash;13&nbsp;days after the administration of methotrexate. Myelosuppression and mucositis are generally reversible within 14&nbsp;days in patients with unimpeded elimination mechanisms.</p><p>&nbsp;</p><p>The most commonly reported side effects are thrombocytopenia, leukopenia, headache, dizziness, cough, loss of appetite, diarrhoea, abdominal pain, nausea, vomiting, inflammation and ulceration of the mucous membranes of the mouth and throat (mainly within the first 24&ndash;48&nbsp;hours after the use of methotrexate), elevated liver enzymes and bilirubin levels, alopecia, reduced creatinine clearance rates, fatigue and malaise.</p><p>&nbsp;</p><p>The ulceration of the mucous membrane of the mouth is usually the first clinical sign of toxicity.</p><p>&nbsp;</p><p>The evaluation of adverse reactions is based on the following frequencies:</p><p>Very common: &nbsp;&nbsp;&nbsp; &ge;1/10</p><p>Common: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/100, &lt;1/10</p><p>Uncommon: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/1000, &lt;1/100</p><p>Rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;1/10,000, &lt;1/1000</p><p>Very rare: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;1/10,000</p><p>Not known&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p><strong>Infections and infestations</strong></p><p><u>Common:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes zoster</p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; opportunistic infections, which may be fatal</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sepsis (including fatal outcomes)</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; herpes simplex hepatitis, cryptococcosis, histoplasmosis, cytomegalovirus infections (including pneumonia), disseminated herpes simplex, nocardiosis, pneumocystis jirovecii pneumonia*</p><p><u>Not known:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumonia, reactivation of a hepatitis B infection, worsening of a hepatitis C infection</p><p>&nbsp;</p><p><strong>Benign, malignant and unspecified neoplasms (including cysts and polyps)</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; malignant lymphoma*</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tumour lysis syndrome*</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Blood and lymphatic system disorders*</strong></p><p><u>Very common:</u> leukopenia, thrombocytopenia</p><p><u>Common</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anaemia, pancytopenia, myelosuppression, agranulocytosis</p><p><u>Rare:</u> &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; megaloblastic anaemia</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aplastic anaemia, eosinophilia, neutropenia, lymphadenopathy (at times reversible), lymphoproliferative disorders (partially reversible)</p><p>&nbsp;</p><p><strong>Immune system disorders</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; allergic reactions including anaphylactic shock, immunosuppression</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypogammaglobulinaemia</p><p>&nbsp;</p><p><strong>Metabolism and nutritional disorders</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; diabetes mellitus</p><p><u>&nbsp;</u></p><p><strong>Psychiatric disorders</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; depression</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mood swings, transient cognitive disorders</p><p>&nbsp;</p><p><strong>Nervous system disorders</strong></p><p><u>Very common:</u> headaches, dizziness</p><p><u>Common:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness, paraesthesia</p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; hemiparesis, confusion, seizures (in the case of parenteral administration), leukoencephalopathy/encephalopathy* (in the case of parenteral administration)</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; paresis, speech disorders including dysarthria and aphasia, myelopathy (after lumbar application)</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness and pain in the extremities, dysgeusia (metallic taste in the mouth), acute aseptic meningitis, meningismus (paralysis, vomiting), cranial nerve syndrome, paraesthesia/hypoaesthesia</p><p><u>Not known:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; neurotoxicity, arachnoiditis, paraplegia, stupor, ataxia, dementia, increased pressure of the cerebrospinal fluid</p><p>The intravenous use of methotrexate may also lead to acute encephalitis and fatal acute encephalopathy.</p><p>&nbsp;</p><p><strong>Eye disorders</strong></p><p><u>Common:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; conjunctivitis</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; visual disturbances (at times severe), severe retinal vein thrombosis</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; periorbital oedema, blepharitis, epiphora, photophobia, transient blindness, loss of vision</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Cardiac disorders</strong></p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pericarditis, pericardial effusion, pericardial tamponade</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Vascular disorders</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; vasculitis, allergic vasculitis</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypotension, thromboembolic events (including arterial thrombosis, cerebral thrombosis, thrombophlebitis, deep vein thrombosis)</p><p>&nbsp;</p><p><strong>Respiratory, thoracic and mediastinal disorders*</strong></p><p><u>Very common:</u> cough</p><p><u>Common:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung complications on the basis of interstitial alveolitis/pneumonitis, and resulting death (regardless of dosage and duration of therapy with methotrexate)</p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; pleural effusion, pulmonary fibrosis</p><p><u>Rare:</u> &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pharyngitis, respiratory arrest, pulmonary embolism</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic interstitial lung disease, bronchial asthma-like reactions such as cough, dyspnoea and pathological findings in the lung function test</p><p><u>Not known:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain, hypoxia, pulmonary alveolar bleeding (was reported with the use of methotrexate in rheumatologic and related indications)</p><p>&nbsp;</p><p><strong>Gastrointestinal disorders*</strong></p><p><u>Very common:</u> loss of appetite, diarrhoea (mainly within the first 24&ndash;48&nbsp;hours after use of methotrexate), abdominal pain, nausea, vomiting, inflammation and ulceration of the mucous membranes of the mouth and throat (mainly within the first<br />24&ndash;48&nbsp;hours after use of methotrexate)</p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal ulceration and bleeding, pancreatitis</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enteritis, gingivitis, melena</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haematemesis</p><p><u>Not known</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-infectious peritonitis, toxic megacolon, intestinal perforation, glossitis</p><p>&nbsp;</p><p><strong>Hepatobiliary disorders* </strong></p><p><u>Very common:</u> increase in hepatic enzymes (ALT [GPT], AST [GOT]), alkaline phosphatase and bilirubin</p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; hepatotoxicity, hepatic steatosis, chronic liver fibrosis and cirrhosis, decrease in serum albumin</p><p><u>Rare:</u> &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute hepatitis</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute hepatic necrosis, acute liver decay, liver failure</p><p><strong>&nbsp;</strong></p><p><strong>Skin and subcutaneous tissue disorders*</strong></p><p><u>Very common:</u>&nbsp; alopecia</p><p><u>Common:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; exanthema, erythema, itching, photosensitivity, skin ulceration</p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; severe toxic phenomena: herpetiform skin eruptions, Stevens-Johnson syndrome*, toxic epidermal necrolysis (Lyell&rsquo;s syndrome)*; urticaria, hyperpigmentation of the skin, nodulosis, painful erosions of psoriatic plaques, wound healing disorders</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne, petechiae, ecchymoses, erythema multiforme, erythematous skin rash, hyperpigmentation of the nails, onycholysis</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; furunculosis, telangiectasia, acute paronychia</p><p><u>Not known:</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drug reaction with eosinophilia and systemic symptoms (DRESS), exfoliation of the skin/exfoliative dermatitis</p><p>&nbsp;</p><p><strong>Musculoskeletal, connective tissue and bone disorders</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; arthralgia, myalgia, osteoporosis</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stress fracture</p><p><u>Not known</u>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; osteonecrosis e.g., of the jaw (secondary to lymphoproliferative diseases)</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Renal and urinary tract disorders*</strong></p><p><u>Very common:</u> decreased creatinine clearance</p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; nephropathy, renal failure, cystitis with ulcerations (possibly with haematuria), urinary retention, dysuria, oliguria, anuria</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperuricemia, increased urea and creatinine concentrations in serum, azotaemia</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haematuria, proteinuria</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Pregnancy, postpartum and perinatal conditions</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; foetal malformations</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abortion</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; foetal death</p><p>&nbsp;</p><p><strong>Reproductive system and breast disorders</strong></p><p><u>Uncommon:</u> &nbsp;&nbsp;&nbsp;&nbsp; vaginal ulcerations and inflammation</p><p><u>Rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; transient oligospermia, transient menstrual disorders</p><p><u>Very rare:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impaired oogenesis/spermatogenesis*, infertility*, menstrual disorders, loss of libido, impotence, vaginal discharge, gynaecomastia</p><p><u>Not known:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urogenital dysfunction</p><p><strong><u>&nbsp;</u></strong></p><p><strong>General disorders and symptoms in the area of administration</strong></p><p><u>Very common:</u> exhaustion, malaise</p><p><u>Uncommon</u>: &nbsp;&nbsp;&nbsp;&nbsp; pyrexia, in <strong>intramuscular application </strong>of methotrexate, <strong>local side effects </strong>(burning sensation) or damage (sterile abscesses formation, destruction of fatty tissues) at the administration site may occur</p><p><u>Not known:</u> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills, necrosis at the injection site, oedema</p><p>&nbsp;</p><p>* For information on serious side effects, see Section&nbsp;4.4.</p><p>&nbsp;</p><p><strong><u>Side effects of intrathecal application of methotrexate</u></strong></p><p>The CNS toxicity that may occur following intrathecal use of methotrexate may manifest differently:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acute chemical arachnoiditis (inflammation of the arachnoid membrane) that manifests, e.g., through headache, back pain, stiff neck and fever, for example;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sub-acute myelopathy, that is characterised, for example, by paraparesis/paraplegia (involving one or more roots of the spinal nerves);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chronic leukoencephalopathy, which is characterised, for example, by confusion, irritability, drowsiness, ataxia, dementia, seizures and coma. This CNS toxicity may progress and even lead to death.</p><p>&nbsp;</p><p>There is some evidence that the combined use of cranial irradiation and intrathecal methotrexate increases the incidence of leukoencephalopathy. Following the intrathecal administration of methotrexate, close monitoring for possible signs of neurotoxicity (irritation of the meninges, temporary or permanent paralysis, encephalopathy) must be carried out.</p><p>&nbsp;</p><p>The intrathecal and intravenous use of methotrexate can also cause acute encephalitis and acute encephalopathy, which can lead to death.</p><p>&nbsp;</p><p>There are reports of patients with periventricular CNS lymphoma who developed a cerebral herniation following the intrathecal application of methotrexate.</p><p>&nbsp;</p><p><strong><u>Side effects with intramuscular use of methotrexate</u></strong></p><p>Following intramuscular use of methotrexate, local side effects at the injection site (burning sensation) or damage (sterile abscess formation, necrosis of fatty tissue) can occur.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms of an overdose</u></p><p>Experience post market launch of methotrexate has demonstrated that a methotrexate overdose generally occurred after oral, but also after intravenous, intramuscular or intrathecal administration. In the reports for oral overdose, the weekly dosage was accidentally administered daily (as a full dose or divided into several separate doses).</p><p>&nbsp;</p><p>Symptoms following oral and/or intravenous overdose primarily affect the haematopoietic and gastrointestinal system. For example, leukopenia, thrombocytopenia, anaemia, pancytopenia, neutropenia, myelosuppression, mucositis, stomatitis, mouth ulcers, nausea, vomiting and gastrointestinal ulceration and bleeding occurred. In some cases, there were no signs of intoxication. There are reports of overdose deaths. In these cases, sepsis, septic shock, renal failure and aplastic anaemia were reported.</p><p>&nbsp;</p><p>After an intrathecal overdose, CNS symptoms generally occur associated with headache, nausea and vomiting, seizures or convulsions and acute toxic encephalopathy. In some cases, no symptoms were observed. In other cases, the intrathecal overdose had a fatal outcome, whereby cerebral herniation together with increased intracranial pressure and acute toxic encephalopathy were reported.</p><p>&nbsp;</p><p><u>Therapeutic measures in the case of an overdose</u></p><p>Calcium folinate, the specific antidote, is available for the prevention and therapy of toxic side effects.</p><p>&nbsp;</p><p>a)&nbsp;&nbsp;&nbsp;&nbsp; Prevention:</p><p>In the case of a methotrexate dosage from 100&nbsp;mg/m<sup>2</sup> body surface area, the use of calcium folinate must follow this therapy. For the dosage and duration of use of calcium folinate as an antidote, please refer to the specific professional literature.</p><p>&nbsp;</p><p>b)&nbsp;&nbsp;&nbsp;&nbsp; Therapy:</p><p>Treatment of intoxication symptoms following a low-dose methotrexate therapy (single dosage &lt;100&nbsp;mg/m<sup>2</sup> BSA methotrexate) that can be attributed to tetrahydrofolic acid deficiency:</p><p>Immediately 6&ndash;12&nbsp;mg calcium folinate intravenously or intramuscularly. Then several administrations (at least four times) of the same dosage at 3&ndash;6&nbsp;hourly intervals.</p><p>&nbsp;</p><p>For intensified calcium folinate rescue in delayed methotrexate elimination under therapy with methotrexate in medium and high dosages, please refer to the specific professional literature.</p><p>&nbsp;</p><p>With an increasing time interval between the administration of the methotrexate and the calcium folinate, the efficacy of the calcium folinate decreases. To determine the optimal dosage and duration of the calcium folinate administration, the methotrexate serum level must be monitored.</p><p>&nbsp;</p><p>In the case of a massive overdose, hydration and alkalinisation of the urine may be necessary to avoid sedimentation of methotrexate and/or its metabolites in the renal tubules. If intoxication should be caused by a substantially delayed elimination (methotrexate serum levels), such as due to acute kidney failure, haemodialysis and/or haemoperfusion may have to be considered. An effective methotrexate clearance was achieved by haemodialysis with a high-flux dialyser. Neither standard haemodialysis nor peritoneal dialysis resulted in improved methotrexate elimination.</p><p>&nbsp;</p><p>An accidental intrathecal overdose may require intensive systemic countermeasures:</p><p>High <strong>systemic &ndash; <u>not intrathecal!</u></strong> <strong>&ndash;</strong> calcium folinate administration, alkaline diuresis, rapid drainage of the cerebrospinal fluid and ventriculo-lumbar perfusion.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agent, antimetabolite, folic acid analogue ATC code: L01BA01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>As a folic acid analogue, methotrexate belongs to the class of medicinal products called antimetabolites. It competitively inhibits the dihydrofolate reductase enzyme. Via this enzyme, dihydrofolic acid must be reduced to tetrahydrofolic acid before it can be used to transport a carbon group in the synthesis of purine nucleotides and thymidylates. As a result, methotrexate is actively involved in DNA synthesis and repair as well as in cell replication.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>Highly proliferating tissue, such as malignant cells, bone marrow, foetal cells, epithelium and mucosa, is generally more sensitive to this effect of methotrexate. Cell proliferation is usually more pronounced in malignant tumours than in normal tissue, and methotrexate can therefore sustainably affect malignant growth without causing irreversible damage to normal tissue.</p><p><em>&nbsp;</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Resorption</em></p><p>100% with intravenous and intramuscular administration.</p><p>&nbsp;</p><p>Following oral administration, methotrexate is resorbed from the gastrointestinal tract. At low dose administration (7.5&nbsp;mg/m<sup>2 </sup>to 80&nbsp;mg/m<sup>2 </sup>body surface area), the average bioavailability of methotrexate is approximately 70%, but significant inter- and intra-subject variability (25&ndash;100%) is possible. Maximum serum concentrations are reached within 1&ndash;2&nbsp;hours.</p><p>&nbsp;</p><p>Subcutaneous, intravenous and intramuscular administrations revealed similar bioavailability. Approximately 50% of methotrexate is bound to serum proteins. After distribution, it collects mainly in the liver, kidneys and spleen in the form of polyglutamates, which can be retained for weeks or months.</p><p>In intrathecal methotrexate application, resorption into the plasma compartment only takes place slowly and causes a potentially toxic plasma concentration to be maintained over a longer period of time.</p><p>&nbsp;</p><p><em>Distribution</em></p><p>After intravenous application, the initial distribution volume is approx. 0.18&nbsp;l/kg (18% of the body weight) and at steady-state conditions approx. 0.4&ndash;0.8&nbsp;l/kg (40&ndash;80% of the body weight). Methotrexate competes with reduced folates for the active carrier-mediated cell membrane transport. At serum concentrations above 100&nbsp;&mu;mol/l, the intracellular concentration is achieved mainly by passive diffusion.</p><p>The plasma protein binding of methotrexate is approximately 50%.</p><p>Methotrexate achieves the highest concentrations in the kidney, gallbladder, spleen, liver, skin, and in the large and small intestines. Methotrexate passes slowly into the so-called &ldquo;third space&rdquo; (pleural effusions and ascites) from whence it is released in a delayed manner (whereby a possible increase in toxicity can occur!). When administered orally and parenterally at therapeutic doses, methotrexate does not penetrate the blood-CSF barrier. Therapeutically effective doses in the cerebrospinal fluid can be achieved only after intrathecal administration or maximum dose therapy.</p><p>&nbsp;</p><p>In low dosages, only minimal amounts of methotrexate pass into the cerebrospinal fluid; at high dosages (300&nbsp;mg/kg body weight), concentrations of between 4 and 7&nbsp;&mu;g/ml were measured in the cerebrospinal fluid. The terminal half-life is on average 6&ndash;7&nbsp;hours and shows considerable fluctuations (3&ndash;17&nbsp;hours). In patients with a third distribution space (pleural effusion, ascites), the half-life may be up to four times longer.</p><p>&nbsp;</p><p><em>Biotransformation</em></p><p>After absorption, methotrexate is metabolised both hepatically and intracellularly to polyglutamates, which can be converted back to methotrexate by hydrolase enzymes. These polyglutamates act as inhibitors of dihydrofolate reductase and thymylate synthetase. Small amounts of methotrexate polyglutamates can remain in tissue for a long time. The retention and prolonged effect of these active metabolites vary depending on the type of cells, tissue and tumours. In conventional doses, a small amount is metabolised to 7-hydroxymethotrexate; in high-dose therapy, the accumulation of this metabolite can be significant. The water solubility of 7‑hydroxymethotrexate is three to five times lower than that of the starting compound.</p><p>The <u>terminal half-life</u> following administration of low-dose methotrexate (30&nbsp;mg/m&sup2; BSA) is approx. 3&ndash;10&nbsp;hours. In high-dose therapy, the terminal half-life is 8&ndash;15&nbsp;hours.</p><p>&nbsp;</p><p><em>Elimination</em></p><p>The elimination of methotrexate is mainly renal by&nbsp;glomerular filtration and active secretion in the proximal tubule and is dependent on the dosage and application method. When administered intravenously, 80&ndash;90% of the dose administered is excreted unchanged in the urine within<br />24&ndash;30&nbsp;hours. Biliary excretion is limited and equals a maximum of 10% of the administered dose. Methotrexate is subject to extensive enterohepatic circulation, so that a maximum of 10% of the administered dosage is excreted via the faeces. Methotrexate undergoes a short distribution phase lasting a few minutes after intravenous injection and is eliminated during a second<br />12&ndash;24 hour period with a plasma half-life of 2&ndash;3 hours as well as during a third phase with a plasma half-life of 12&ndash;24 hours. In the case of impaired renal function, delayed elimination is to be expected, which can result in serious side effects. A&nbsp;good correlation between methotrexate clearance and endogenous creatinine clearance was determined. Limitations in excretion with impaired liver function are currently not known.</p><p>Methotrexate breaks through the placental barrier in rats and monkeys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Chronic toxicity</u></p><p>In tests for chronic toxicity in mice, rats and dogs, toxic effects were identified in the form of gastrointestinal lesions, myelosuppression and hepatotoxicity.</p><p>&nbsp;</p><p><u>Mutagenic and carcinogenic potential</u></p><p>Long-term studies in rats, mice and hamsters showed no evidence of a tumourigenic potential of methotrexate. Methotrexate induces in vitro and in vivo gene and chromosome mutations. There is a suspicion of a mutagenic effect in humans.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>Teratogenic effects have been reported in four species (rats, mice, rabbits, cats). No malformations comparable with humans occurred in Rhesus monkeys.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium hydroxide, water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Known incompatibilities:</u></p><p>Potent oxidants and acids</p><p>Chlorpromazine HCl (cloudy and yellow precipitate)</p><p>Droperidol</p><p>Idarubicin</p><p>Metoclopramide HCl</p><p>Prednisolone sodium phosphate</p><p>Promethazine HCl</p><p>&nbsp;</p><p>In addition, incompatibilities of methotrexate and cytarabine and fluorouracil have been reported, but the incompatibility with fluorouracil is questionable.</p><p>As a rule, finished infusion solutions should be used within a maximum of 24&nbsp;hours after preparation; in addition, incompatibilities with other substances may occur with prolonged storage (e.g., bleomycin).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
The medicinal product must be used immediately after opening. 
For single use only. Dispose of any unused product.


For Methotrexat “Ebewe”, the stability is tested under light protection at 25°C (room temperature) over 24 hours for the following solutions:
5% glucose solution
0.9% sodium chloride solution

Solution for infusion after dilution
The ready-to-use preparation has been shown to be chemically and physically stable for 28 days at 2°C to 8°C and at room temperature protected from light.

From a microbiological point of view, the reconstituted preparation should be used immediately. If the reconstituted preparation is not used immediately, the user is responsible for the duration and conditions of storage. If the ready-to-use solution is not prepared under controlled and validated aseptic conditions, it should not be stored for longer than 24 hours at 2°C to 8°C.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>Store in the original packaging in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vials</p><p>Vials with/without transparent plastic containers (Onco-Safe)</p><p>&nbsp;</p><p>Pack sizes:</p><p>Vials: 1 / 5&nbsp;x&nbsp;5&nbsp;ml, 1 / 5&nbsp;x&nbsp;10&nbsp;ml, 1&nbsp;x&nbsp;50&nbsp;ml</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before use, the solution must be visually inspected.</p><p>Only clear solutions, virtually free from particles, may be used.</p><p>&nbsp;</p><p>Any contact of methotrexate with the skin or mucosa must be avoided!</p><p>If contaminated, the affected areas must be rinsed immediately with copious amounts of water.</p><p>&nbsp;</p><p><em><u>Note for medical personnel:</u></em></p><p>As in general when handling cytostatics, extreme caution is also advised when handling methotrexate; gloves, face mask, protective clothing and air extraction if possible. Skin and mucosal contact must be avoided. Pregnant persons should avoid any contact with methotrexate.</p><p>&nbsp;</p><p>Handling and disposal specifications specified for cytostatic agents must be observed.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with national requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EBEWE Pharma GmbH, 
Nfg.KG, 4866 Unterach, 
Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                May 2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>